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ABSTRACT
SMALL CELL CANCER OF THE LUNG:
AN INITIAL EVALUATION OF THE YALE TREATMENT PROTOCOL
David Jonathan Birnkrant
1985

A review of small cell cancer of the lung (SCCL) is presented,
followed by initial results from the Yale University treatment
protocol for SCCL.
The review includes selected topics on the epidemiology,
etiology,

cytogenetics, cytomorphology,

products,

clinical diagnosis,

SCCL.

staging,

cells of origin,
prognosis,

cell

and treatment of

The tumor emerges as one of diverse clinical behavior and

cellular character; it remains poorly understood.
intermediate or slow doubling time,

Despite

dissemination of the

tumor—microscopic or gross—is the rule at diagnosis.

Modest success

has been achieved in treatment, allowing a small group of patients to
go on to long-term survival (4 or 5 years),

but most patients relapse

after initial response to therapy and second-line therapy is rarely
effective.

Special attention is paid to treatment design,

the role of prophylactic cranial irradiation (PCI),

including

adjuvant radiation

therapy, and the concept of local tumor control.
Results from the Yale University treatment protocol are
presented.

Thirty-nine evaluable patients were prospectively

randomized to therapy with cyclophosphamide,

Adriamycin, and

vincristine (CAV) every 21 days or CAV alternating with Etoposide

(VP-16-213).

All limited disease (LD) patients underwent thoracic

irradiation; complete responders received PCI. Eighty percent of LD
patients achieved complete response as did 12% of extensive disease
(ED) patients.

Projected median survival ranged from 198 days for ED

non-responders to 560 days for LD complete responders.
early to report on long-term survival.

It is too

Addition of Etoposide (E)

afforded no significant survival advantage over the CAV regimen.
Etoposide added no significant additional toxicity; in fact,

the

percentage of patients experiencing infections requiring
hospitalization was lower in the CAV/E group (6% vs.

33%).

be the result of a smaller proportion of patients on CAV/E
experiencing leukopenia (44% vs.

76%).

This may
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SMALL CELL CANCER OF THE LUNG:
AN INITIAL EVALUATION OF THE YALE TREATMENT PROTOCOL
PART ONE:

THE BASICS

Introduction

Small cell cancer of the lung (SCCL) is a disease whose
significant incidence and poor prognosis make it of major concern.
This is especially true in a society like ours, with its increasing
emphasis on preventive medicine and the containment of health care
costs.

The etiologic factors in the disease—tobacco smoking,

ionizing radiation, asbestos and chemicals—make SCCL somewhat
preventable.

Treatment for SCCL is often initially effective,

but

relapse is the rule and the disease then proves resistant to secondline therapies.

In light of the relatively poor results achieved with

today's state-of-the-art therapy,

it would be wise to direct concerted

efforts toward prevention of SCCL.^

Unfortunately,

the medical

profession has made no successful attempt to wrest responsibility for
such a goal from businessmen and politicians.

As long as tobacco

remains an important, heavily subsidized cash crop and images from
Madison Avenue dictate our behavior,

the individual medical

practitioner—haranguing his patients about smoking—will remain at
best a nagger, at worst a bore.
This paper will emphasize the diversity in data on SCCL.

Even

the most basic aspects of the disease are poorly understood and the
lack of an effective treatment strategy reflects that ignorance.

The

2

first part of the paper takes the form of a review;

the second part

presents initial data from the Yale University treatment protocol for
SCCL.

Epidemiology and Etiology

Lung cancer death rates have been increasing at a spectacular
rate when compared to that of other cancers.

2

After World War II,

lung cancer death rates for men began rising at a faster rate than
straightline projections would have predicted.

The rate curve for

women has followed suit for the last twenty years.

1 2
’

Projections for

1984 show that lung cancer will be the most common cause of cancer
deaths for men and the second most common cause of cancer deaths for
women.

2
3

Weiss has reviewed numerous studies on the incidence of SCCL.
He reports W.E. Morton's unpublished data on SCCL rates in Portland,
Oregon for the period 1968-1972.
than women.

The disease was more frequent in men

Mean annual rates per 100,000 population were 13 for
4

males, 4 for females.

In contrast, Annegers et al.

reported a rate

of 6/100,000 among males in rural Olmstead County, Minnesota for the
period 1965-1974.

This lower rate is consistent with the notion that

SCCL is less common in rural areas.^
The median age at diagnosis in most series is about 60 years.^
The Philadelphia Pulmonary Research Project studied the natural
history of lung cancer in men 45 years of age and older,
was followed for ten years.

each of whom

Unpublished data from the study,

quoted

3

3
by Weiss,
of age.

show the highest incidence of disease among men 55-64 years
The study reported the highest rate of lung cancers in

general, irrespective of subtype,
group.

in the 60- to 64-year-old age

In contrast, Annegers et al.

4

found their highest incidence

rate among men 75 years or older for the period 1965-1974.
SCCL is generally quoted as accounting for 20-25% of all lung
cancers.^

When the data are examined, however,

the frequency of small

cell as a percentage of all typed cancers varies widely.

In Weiss’s

3
review,

SCCL accounts for 13.7% - 39.6% of all typed lung cancers

among men and 9.4% - 31.3% of lung cancers among women, depending on
the study consulted.

Perhaps these ranges represent differences in

histological interpretation,

or differences in incidence related to

the population observed (the highest relative incidence figures come
8
from a study done in Iceland ).
lung cancer in young adults,

Kyriakos and Webber,

9

reporting on

have found a rate of 13% SCCL among

patients of all ages with lung cancer at Barnes Hospital,

St. Louis.

Their review of the literature revealed that SCCL accounted for 2-38%
of lung cancers in several large series.

Interestingly,

these authors

found a slightly higher relative incidence of SCCL (24%) among younger
patients (45 years of age or less).

Kennedy^ found a remarkably high

proportion of small cell tumors (65%) in his series of 40 lung cancers
occurring in patients under the age of 40 in England.

In contrast,

Putnam‘S at Walter Reed Army Medical Center found 17% small cell
tumors among 24 patients with lung cancer under the age of 40.

4

The male:female ratio of SCCL is generally thought to be higher
than for other types of lung cancer, with a ratio of 3 males:1 female
reported by Morton.

3

Etiological factors in SCCL include exposure to tobacco smoking,
ionizing radiation,
pollution.

asbestos,

chemicals, metals, and possibly air

Pathogenesis of the disease is not well understood;

the

tumors are usually central in location and are presumed to arise,
squamous cell carcinoma,
denudement,

like

through chronic irritation, mucosal

and absorption of carcinogens.

12
“

The cells of origin of

the tumor are of great interest and will be discussed later on.
There is probably a dose-response relationship between cigarette
consumption and the development of SCCL.

The Philadelphia Pulmonary

Neoplasm Research Project's data supported this notion.
al.

14

13

Auerbach et

found that small cell as a percentage of all lung cancers rose

from 14.5% for ex-smokers progressively to 31.1% for those patients
smoking more than two packs a day.

(See Table 1.)

seen in other histological subtypes.

This rise was not

Of note is the possibility that

cessation of smoking is associated with longer survival in SCCL,

even

when patients stop at the time of diagnosis.^
The link between exposure to ionizing radiation and SCCL is a
strong one.

Archer et al.

10

compared rates of lung cancer and its

subtypes among uranium miners to the rates expected for a matched
group without radiation exposure.

The authors expected to find 14.06

respiratory cancers in their study group.
recorded among the miners,

Instead,

107 cases were

66 of which were SCCL (62%).

In the

5

matched control group, SCCL should have accounted for 14.05% of the
lung cancers.

There was,

in addition, a dose-response relationship

found for SCCL with increasing radiation exposure.
in Table 2.

Unlike smoking,

These data appear

then, radiation exposure may produce a

predominance of small cell cancers in the lung.

Agreement on this

point is not universal, however.^
Asbestos and chemicals have been implicated in the etiology of
lung cancers in general.

Although data on subtypes is limited, SCCL

appears to be associated with exposure to these agents.

The role of

smoking in the carcinogenicity of asbestos is still not clear;

is

asbestos a carcinogen or a synergistic agent which promotes cancer in
smokers?

The chemicals for which there is evidence of carcinogenicity

in humans include:

"polycyclic aromatic hydrocarbons, certain metals
3

or their compounds, and certain simple organic chemicals."
of possible carcinogens grows longer every day,

The list

but the strict

scientific criteria needed to show causality make such proof a task
that is pain-staking, if not impossible.

Cytogenetics, Cytomorphology, Cells of Origin,
and Cell Products

The basis of understanding the small cell tumor lies in an
understanding of its component cells.
through cytogenetic studies.
identifiable characteristics?

One approach to these cells is

Do the chromosomes of the tumor have

6

Wurster-Hill and Maurer

studied the chromosomes of patients'

SCCL tumors using direct bone marrow preparations and trypsin-Giemsa
banding.

Chromosome number and structural aberrations (markers) were

frequent and highly variable.

Chromosome number (ploidy, DNA index)

in untreated patients ranged from hypodiploid to polyploid with the
latter most common (the chromosome count was typically in the
80's).

A structural abnormality of chromosome #1 was found in 14 of

the 18 patients with karyotypic abnormalities (total patients = 26).
But very few markers were common to two or more patients and the
consistency of given markers among the cells from one patient was
usually poor.

The presence of cells with different abnormalities of

chromosome number in the same patient (e.g., diploid and polyploid)
was discovered.

Vindelov et al.

18

found that ploidy in their SCCL

tumor cells could be grouped into near-diploid, near-triploid, and
near-tetraploid values.

Each of five patients was found to have two

clones with different chromosome number in a single metastasis (17% of
the total patients).

The authors view this as evidence that SCCL, at

least for some patients, is not monoclonal.
evolve from the original tumor.
characteristics (clinical,

That is:

new cell lines

These cell lines may have

biochemical) that are entirely different

from those of the original tumor.

The heterogeneity of the SCCL

tumor—a concept emphasized in this paper—may lie in the evolution of
more than one cell line from the original tumor.
Whang-Peng et al.

19

found two distinct stem lines in 2 of their

12 cell lines cultured from human small cell lung cancer tissue.

7

These authors describe a consistent, acquired chromosomal
abnormality—a deletion in the short arm of chromosome #3—present
both in SCCL cell lines and in fresh clinical specimens cultured for 2
days in a serum-free medium.

Chromosome studies of other types of

neoplasms have not shown a specific abnormality of chromosome #3.

The

data of Wurster-Hill and Maurer (abnormality of chromosome #1) do not
fit easily into the scheme of Whang-Peng et al.; an explanation of the
discrepancies awaits elucidation.

Whang-Peng et al. appear to have

found a specific, acquired somatic cell defect (deletion 3p,
associated with continued replication of SCCL tumor cells.
holds true,

14-23)
If this

the diagnosis and treatment of SCCL will be

aided—especially if the function of the genes present in the region
of chromosome #3 where the deletion was found can be understood.
Another approach to the cells of the tumor is to ask:
SCCL arise from?

where does

That is, which cells in the lung first acquire the

chromosomal abnormalities,

due to exposure to carcinogens, which lead

to the growth of a tumor?
Hattori et al.

20

studied 24 cases of oat-cell (small cell)

carcinoma of the lung and four cases of bronchial carcinoid tumor both
under the electron microscope and biochemically.

They found that SCCL

tumor cells were characterized by the presence of neurosecretory-type
granules (NSGs) of 800-2000 Angstroms, almost identical to but
somewhat smaller than the NSGs found in 4 samples of bronchial
carcinoid tumor.

NSGs were not found in 139 samples of other types of

lung tumors studied.

Serum serotonin level was elevated in 13 of 20

8

small cell cases and the degree of elevation seemed to correlate with
the number of NSGs present in the tumor cells.

Serotonin level in

tumor tissue was elevated in 7 of 12 cases of SCCL but in only 1 of 4
cases of bronchial carcinoid tumor.

In 5 of 7 cases of SCCL, both

serotonin and ACTH were elevated in tumor tissue samples.
of lung cancer, which lacked NSGs,

Other types

showed no elevation of serotonin

activity with the exception of one case of squamous cell carcinoma
(and one case of pleurisy due to collagen vascular disease).

The

authors noted that the NSGs they found in bronchial carcinoid and SCCL
were identical to those which had been previously described by Bensch
et al.

21

in the Kulchitsky-type cells in bronchial mucus glands.

Hattori et al. thus concluded that "oat-cell carcinoma is a special
type of lung tumor producing neurosecretory-type granules and a highly
malignant variant of bronchial carcinoid tumor which is originated
from neurosecretory-type cell (Kulchitsky-type cell) found in
bronchial glands."

20

This is a remarkable statement,

for the authors

have found an association between electron microscopic characteristics
of the tumor (NSGs) and tumor products (serotonin, ACTH) known to have
clinical significance as ectopic hormone products of SCCL tumors.
Moreover,

22

the ultrastructure of the tumor cells has provided a clue to

cell origin:

the Kulchitsky-type cells of bronchial glands.

The

latter can produce serotonin from tryptophan and 5-hydroxy-tryptophan,
which means they fit into Pearse's conception of an APUD (Amine
23
Precursor Uptake and Decarboxylation) cell."-

APUD origin would,

turn, imply a way of attacking the embryological lineage of SCCL's

in

9

cells of origin and relate SCCL to other cells of APUD origin in the
body.

In fact,

apply them.

the above associations reach beyond our ability to

Indeed, Hattori et al.

24

examined the cytomorphology of

SCCL tumors in relation to response to therapy in an article published
five years after the one already discussed.

Surprisingly, although

almost all SCCL tumor cells were found to contain NSGs,

the cells from

tumors which did not respond to combination chemotherapy showed few or
no NSGs.

Some of the tissue specimens used in the study were obtained

from autopsy material,
the cell structure.

and it is possible that chemotherapy affected

Alternatively, a cell line without NSGs could

have arisen from the original tumor.

Still,

the lack of NSGs in the

non-responder group shakes the foundation of attempts to characterize
SCCL at an ultrastructural level in a way that is consistent with the
presumed cells of origin.
Tischler

25

notes that the APUD concept has been elucidated and

revised since its initial introduction.

APUD cells are now known to

occur in two distributions in the lung:

as scattered Kulchitsky-like

cells and as organized groups of cells called neuroepithelial bodies.
Both occur in close proximity to nerve endings.

The secretory

products and physiological role of APUD cells in the lung are
obscure.

While the APUD concept may explain the source of some of the

hormones SCCL tumors produce,

cytogenetic abnormalities—"derepression

of the genome"—might also account for production of ectopic
hormones.

26

10

Still,

APUD has been used as a window to the study of SCCL's

ectopic hormones.

A wide variety of such hormones have been

identified and include ACTH,
serotonin, PTH,

ADH,

and estradiol.

calcitonin,

18 22 27
’
’

glucagon,

HCG,

The frequency of ectopic

hormone production by small cell tumors is not known; it is clear,
however,

that clinically apparent syndromes that can be traced to

these hormones are much rarer than production of the hormones
themselves.

Thus, while more than 50% of patients may have abnormally

high levels of hormones such as ACTH, ADH and calcitonin, clinical
syndromes such as SIADH or Cushing's syndrome appear to occur in less
than 10% of patients.

28

Richardson et al.

point out that the identity

of these tumor-produced "ectopic hormones" is not really known;

they

may or may not be identical to "normal" hormones and radioimmunoassays
.
28
of these substances may be neither truly sensitive nor specific.
Despite these caveats, Science marches on.

Baylin and Gazdar

29

have measured biochemical indices in SCCL with established
relationships to APUD cells outside the lung.

These include L-dopa

decarboxylase (central to the APUD concept—it converts precursor
amino acids into their corresponding amines); and calcitonin (produced
by the APUD tumor medullary thyroid carcinoma).
histaminase and beta-endorphin,
cell activity;

still,

They also measured

neither of which is specific to APUD

both substances are thought to be involved in

hormone production by cancers.

The authors found that the biochemical

parameters studied were not specific to SCCL and that there was great
heterogeneity of findings between different patients with SCCL,

among

11

different lesion sites (primary vs. metastatic) in the same patient
with SCCL, and even within individual SCCL lesions.

These data are

viewed as a reflection of heterogeneous cell populations all of which
are grouped together under the clinical term "small cell lung
cancer."

The authors noted that quantitatively,

however,

their

endocrine parameters tended to group more with SCCL than with other
lung tumors.
An attempt has been made to find tumor products which will prove
to be specific markers of SCCL, whose concentrations are proportional
to tumor burden, and which are present in enough patients to make
measurement worthwhile.
bombesin,

Three such newly described products are

the BB isoenzyme of creatine kinase (CK-BB), and

neuron-specific enolase (NSE).

I will describe a study of NSE as an

example.
Carney et al.

30

studied serum NSE levels at diagnosis in 94

patients with SCCL. The levels were repeated during and after
therapy.

Sixty-nine percent of all patients had a serum NSE level

more than 3 S.D.

above control, including 87% of the patients with

extensive-stage disease (ED). Mean serum NSE was significantly higher
in patients with ED than in those with limited-stage disease.

In 20

of 21 patients, all of whom had elevated NSE levels at diagnosis,
serum NSE fell significantly as the patients responded to
chemotherapy.

In the one patient whose level remained unchanged, no

response to therapy was achieved and the disease progressed.

The NSE

level dropped into the normal range for all patients achieving a

12

complete response.
Serial NSE measurements showed a good correlation between
clinical condition and the level of the marker.

For example,

in 9

patients with raised NSE levels on diagnosis the levels fell to near
normal range with therapy then rose again when the patients relapsed.
NSE has been identified in all cell lines of SCCL tested; it has not
been found in substantial amounts outside central and peripheral
nervous system tissue,

findings consonant with the fact that APUD

cells and neurons tend to express much of the same genetic
information—they are "neuro-endocrine programmed."

25

NSE thus has

the potential to be a useful marker for SCCL; immunohistochemical
staining of lung tissue for NSE might someday help in making
pathological diagnoses.
A recent cytomorphological finding deserves mention.

SCCL cells

from biopsies and derived cell lines were shown to contain
neurofilament-type intermediate filaments.

31

Since the expression of

these filaments is tissue type specific and thought to be unchanged
after malignant transformation, another line of approach to the APUD
origin and diagnosis of SCCL may have been uncovered.
Despite the uncertainties described, a picture begins to emerge
of the cells that make up SCCL tumors.

At a cytogenetic level,

they

are characterized by variable numbers of chromosomes (ploidy) and a
specific acquired deletion of the short arm of chromosome #3—3p
(14-23).

The cells contain neurosecretory granules and appear to be

of APUD origin.

Although SCCL cells express a variety of biochemical

13

products,

including certain hormones which account for clinical

syndromes associated with the disease,

truly useful biochemical

markers for SCCL, which combine sensitivity and specificity,
include neuron-specific enolase (NSE);

bombesin (BN); and the BB

isoenzyme of creatine kinase (CK-BB). Finally,
collection of multiple cell lines,
between patients,

may

the idea that SCCL is a

both in individual tumors and

is supported by the variety of tumor products and

their levels expressed by cells from single tumor sites; by cells
taken from primary vs. metastatic sites;
found in different patients.

and by cells from tumors

The notion of multiple cell lines is

further supported by the variable number of chromosomes (ploidy)
by Vindelov et al.

18

found

in some tumor samples from a single metastatic

site and by Hattori et al.'s

24

finding of decreased or absent

neurosecretory granules in the cells of tumors unresponsive to
chemotherapy.

The characteristics of SCCL have been further

elucidated by recent studies which build on the picture above.
Tumor cell chromosome number was recently examined in relation to
treatment response by a group at M.D. Anderson Hospital.

32

They found

a DNA index of 0.70 to 2.09 (1.0=diploid) among 126 pre-treatment
specimens.

Six percent of the cases had bi-clonal stem lines.

Hypodiploid tumors had decreased percent S-phase cells (reflecting
lesser proliferative activity).
response,

These tumors showed slower drug

but the response was more prolonged with resultant better

survival when compared to hyperdiploid tetraploid tumors characterized
by high % S-phase cells.

Percent survival at more than 60 weeks could

14

be stratified by DNA index in a significant way,

raising the

possibility that chromosome number and proliferative activity analysis
may one day be used as prognostic criteria.

The presence of more than

one cell line in some tumors was again confirmed.
The use of monoclonal antibodies (MoAbs) may prove to be a useful
method whereby antigenic expression—and thus,
genome—can be studied.

indirectly,

the tumor

Implications for future treatment design are

numerous and include the attachment of anti-tumor drugs to MoAbs,
creating a highly specific tumoricidal agent.
Groups at the NCI have published numerous abstracts in the last
two years reporting on studies in which MoAbs have been applied.
Considerable antigenic heterogeneity has been found within individual
SCCL tumors,

between tumor lines, and,

between clonally related lines.
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to a more limited degree,

SCCL is thus proving to be

heterogeneous in a way that challenges our understanding of cellular
behavior at the level of molecular genetics.

Relative homogeneity has

been found in cell lines from different metastatic sites in the same
patient.

This homogeneity was especially evident when numerous

characteristics of the cells were examined simultaneously:

the

biomarkers dopa decarboxylase (DDC) and bombesin (BN), DNA index,
three forms of antigenic expression (using MoAbs).

34

Still,

and

the

heterogeneity of antigen expression in tumor tissue and the poor
specificity of "tumor" antigens—i.e.,

their diverse distribution in

normal tissue—may cause considerable difficulty in the clinical
application of MoAbs.

35

15

A finding which may prove to be specific is that of HLA-A,B,C,
and beta-2 microglobulin deficiencies on the cell surfaces of human
SCCL lines,

detected by MoAbs. Thusfar, non-SCCL lines have been

strongly positive for these structural markers.

36,37

Two exceptionally interesting reports from the NCI
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have

appeared recently which illustrate our ability to study SCCL at a
cellular level through the use of biochemical markers,

continuous cell

lines, and measurements of radiosensitivity and tumorogenicity.
authors report two major subgroups of SCCL:

The

a classic form, which

expresses DDC, BN, NSE and CK-BB; and a variant form,

which has a

faster doubling time and shorter latent period to tumor induction in
nude mice than the classic form.

The variant form is radioresistant,

nor does it produce DDC or BN in appreciable quantities.

It has

metabolic features which distinguish it from the classic form:
despite the presence of CK-BB,

the product whose formation that enzyme

catalyzes (phosphocreatine) is not present in classic cell lines.
Phosphocreatine isn’t present in non-SCCL lines,

but is present in the

variant cell lines.
The possibility that there are two major subgroups of SCCL—one
clinically aggressive,

resistant to treatment, and lacking the

characteristic APUD enzyme (DDC)—is reminiscent of the findings of
Hattori et al.

2A

Recall that those authors reported on the lack of

neurosecretory granules (NSGs) in a group of tumors resistant to
chemotherapy.

Are Hattori's resistant tumors composed of cells from

the NCI's variant subgroup?

The absence of DDC in a tumor one would

16

expect to be clinically aggressive (the SCCL variant) is like the
absence of NSGs in tumors proven to be therapy-resistant:
characteristics are lacking.

The usefulness of APUD characteristics

in understanding SCCL is not clear.
lines becomes questionable.

basic APUD

The APUD origin of some cell

Perhaps tumor cells lacking NSGs and cell

lines with characteristics of the variant subgroup are highly
aggressive subpopulations of cells which have evolved from the
original,

more indolent APUD-derived tumor.

The concept of classic

and variant cell lines and the presence of more than one cell line in
a tumor also brings to mind the report from M.D. Anderson

32

which

stratified tumor aggressivity by chromosome ploidy and proliferative
activity.
Cytogenetic study of the classic and variant cell lines—
evaluating chromosome number and seeking the deletion in chromosome #3
associated with SCCL

19

—as well as cytomorphological study, with a

special interest in neurosecretory granules, may prove fruitful.
Clearly, researchers are only beginning to explore the cellular basis
of SCCL's clinical behaviors.

Clinical Diagnosis

Cohen and Matthews,^ Matthews and Hirsch^ and Matthews ^ have
reviewed the radiographic,

clinical,

and pathological presentations of

SCCL.
On X-ray, SCCL usually appears as a central mass.
tumor metastasizes early,

Because the

hilar node involvement is common,

with or

17

without mediastinal widening on presentation (64%).

Post¬

obstructive pneumonitis, atelectasis, and pleural effusion (due to
lymphatic blockage) may be present.

Less commonly, a peripheral tumor

mass is seen on presentation (19%).

Very rarely,

the patient presents

with a central tumor mass and no obvious nodes (3%).

The lesion must

be distinguished from epidermoid (squamous cell) carcinoma,
presents as a central lesion.

which also

But epidermoid lesions are rarely

associated with mediastinal adenopathy or widening as evident as that
in SCCL.

Moreover,

SCCL tumors demonstrate central cavitation less

frequently than squamous cell lesions.
While the pathogenesis of SCCL and epidermoid cancer is probably
similar,

there are numerous differences in gross pathology.

Epidermoid tumors are often bulky,

polypoid,

growths, with a friable consistency,
cavitation and liquefaction necrosis.

obstructive intraluminal

with or without central
SCCL,

in contrast,

tends to

form submucosal plaques that spread to involve central
structures:

the trachea, mainstem bronchi, and the bronchial,

and mediastinal lymph nodes.
can be thrombosed,

If the superior vena cava is invaded,

causing SVC syndrome.

secondary to compression.)

hilar,

(SVC syndrome may also arise

SCCL tumors have a glossy grey-white cut

surface that is frequently hemorrhagic and necrotic—but central
cavitation is rare.
Pathological classification of SCCL is based on light
microscopy.

In 1977,

it

the World Health Organization revised their

classification system based on a decade of study.

The subtypes now

18

used include lymphocyte-like or oat cell (#21);
(fusiform,

polygonal,

intermediate forms

"other"—#22); and combined (oat cell with a

definite component of squamous cell or adenocarcinoma).
The nuclear detail of small cell—its fine or coarse stippled
pattern of nuclear chromatin and small,
characteristic.

indistinct nucleoli—is highly

Cytoplasm is usually scanty or may appear to be

absent.

Cells are arranged in a loosely cohesive but clustered

pattern,

forming cords,

sheets,

or pseudorosettes (cuffing around

blood vessels).
There are numerous problems that arise in diagnosing SCCL, as
reviewed by Matthews and Hirsch.

40

These include inadequacy of biopsy

material (biopsy samples that are too small,

bronchial washings or

sputa of equivocal cytology); crushing of tissues, resulting in
overinterpretation of malignancy; and improper tissue processing,
resultant artifacts.

with

The authors contributed to two interobserver

studies designed to identify problems and assess reliability in SCCL
diagnosis.

42 43
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They found unanimity or "near unanimity" (7 of 8

pathologists) in the diagnosis of SCCL in over 90% of the tumors
studied.

The consistency of subtyping of SCCL tumors according to the

1977 WHO criteria was assessed in one of the studies.

Unanimity among

3 pathologists was achieved in only 54% of the cases.

This is a

remarkable figure,

for it raises doubts about all studies designed to

characterize SCCL subtypes (e.g.,

the response of different subtypes

to therapy—a topic to be discussed later).

19

The great majority of patients with SCCL are symptomatic at
presentation.
tumor.

Cough is a common symptom,

Chest pain,

dyspnea,

referable to the primary

symptoms of pneumonitis (due to

obstruction or compression), wheeze and hemoptysis may occur.
12 44
’

Table 3.)

Mediastinal extension of the tumor results in

hoarseness or SVC syndrome,

the former secondary to involvement of the

recurrent laryngeal nerve (usually on the left,
longer).

(See

where its course is

SVC syndrome tends to be associated with right lung tumors,

since the superior vena cava passes through the chest on the right.
Early, widespread metastases are the hallmark of SCCL and
contribute to its symptomatology.
series of 375 patients,

Livingston et al.,

then,

effusion.

bone marrow,
(See Table 4.)

followed closely by

brain, skin/soft tissue/nodes,
45

and pleural

Thirty-seven percent of these patients

had involvement of more than one metastatic site,
in a study of 106 patients at the NCI.
sites,

in their

found liver to be the metastatic site most

often involved in extensive-disease patients,
bone;

45

46

in contrast to 49%

The significant metastatic

in terms of symptomatology, are bone and brain, causing pain

and neurological complaints,

respectively.

Although cardiac

involvement is rarely mentioned in clinical series,

20-25% of SCCL

patients have been reported to have cardiac metastases at
autopsy.

12,14
’

(See Table 4.) Such involvement can result in signs and

symptoms of heart failure,

EKG changes,

even tamponade.

Adriamycin,

commonly used in treatment protocols for SCCL, has cardiotoxic side
effects; thus,

ejection fractions are routinely computed at the start

20

of therapy.

Still, one wonders what implications subclinical cardiac

involvement might have with respect to treatment complications.
The existence of clinical syndromes related to ectopic hormone
production by SCCL tumors has already been mentioned.
SIADH,

reported in 5-10% of most series,

All are rare.

seems to occur most

frequently in association with SCCL when the cause of SIADH is
neoplastic.

22

CNS manifestations predominate in symptomatic patients

and may include seizures,
extrapyramidal signs.

disorders of consciousness, and

The patient is unable to excrete a maximally

dilute urine when presented with a water load and such testing can
uncover many subclinical cases.
hyponatremia,

Fluid restriction helps correct the

but chemotherapy is the definitive approach.

Ectopic ACTH production is clinically significant in 3-7% of
patients with SCCL.
make the hormone.

22

Numerous tumors thought to be of APUD origin

Symptomatic patients rarely present with the

classic features of Cushing's syndrome—instead,
weakness,

glucose intolerance,

weight loss,

severe

edema and/or hypertension are more

likely presentations of their hypercortisolism.

The metabolic

complications of symptomatic ACTH overproduction can be severe and
management is difficult,

although Greco et al.

22

report early evidence

that combination chemotherapy can be effective.
Paraneoplastic syndromes other than ectopic hormone production
have been found to be associated with SCCL.

Possible etiologies of

these syndromes include viral agents, autoimmune phenomena, and
humoral substances elaborated by the tumor.^

21

Eaton-Lambert syndrome is associated with SCCL more often than
with other diseases.

22

It is an unusual clinical entity,

characterized by the dichotomous findings of proximal muscle weakness
with difficulty walking coupled with facilitation of muscular
potentials on repeated stimulation.

Thus,

the patient's grip may

become stronger and stronger during testing.

The syndrome tends to

occur among male patients over 40 years of age and seems to respond to
cytotoxic therapy.

Should chemotherapy fail,

guanidine may be

effective by causing increased release of anticholinesterases.

22

The

electromyogram is diagnostic.
A final syndrome requiring mention is paraneoplastic
encephalopathy.

22

This is thought to be the cause of death in two

patients in the present study.
the cerebrum,

brainstem,

Clinically,

optic nerves,

the syndrome may involve

and cerebellum.

Pathologic

lesions are generally found in all these regions, although involvement
of one area may dominate the clinical picture.
common manifestation of cerebral involvement.

Dementia is the most
Radiologic studies are

normal; the CSF may show an elevated protein level; the E<EG is often
slow and diffuse.

Staging and Prognosis

There is a TNM (tumor-nodes-metastases) staging system for SCCL
but its use,

until recently,

had fallen out of favor.

The TNM system

is surgically-oriented and poor therapeutic results have been achieved
using surgery alone.

TNM was viewed as prognostically useless.

More

22

recently,

however,

interest in surgery as an adjuvant therapy (part of

a multimodal therapeutic approach) has been revived and the TNM system
may yet take its place as a standard method of staging.
section on treatment.)

(See the

Still, the system of the Veterans

Administration Lung Cancer Study Group remains the one employed in
almost all current studies.

It divides patients into limited-stage

(LD) and extensive-stage (ED) disease groups.

LD is defined as tumor

confined to one hemithorax with or without mediastinal
lymphadenopathy, with or without ipsilateral supraclavicular node
involvement.
portal.
disease.

The tumor must fit within a single radiation therapy

Tumor beyond these confines is defined as extensive
47

In general,
with LD.

5 48 49
’
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two-thirds of all patients present with ED;
Ihde and Hansen

48

have pointed out that,

one-third

with very

thorough diagnostic work-ups, more patients with metastatic disease
not easily detectable are placed in the ED group.

When this is done,

survival data for the individual ED and LD groups may appear improved,
since a group of relatively "healthy" ED patients is created by
removing a group of relatively "sick" LD patients.
(ED + LD) does not change.

Overall survival

The truth of this observation must be

supplemented by the observation that,

despite the sophistication of

the technology available to the physician determined to uncover the
most retiring metastasis,

test results are often equivocal.

It is not

clear whether or not to include certain patients in the ED group and
they may be given the "benefit of the doubt"—identified as patients

*
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with limited disease so that they might enter the LD treatment group.
When this happens,

the survival of the ED group presumably goes up and

that of the LD group goes down.

Again, overall survival remains

unchanged.
Involvement of certain metastatic sites has been found to have
prognostic significance.

More fundamentally, extent of disease has

strong prognostic implications.

Staging procedures in SCCL must be

designed with these facts in mind.

Diagnostic modalities must be

selected for their combination of sensitivity and specificity.
Chest X-ray remains the basic method by which intrathoracic
disease is evaluated.

However,

fiberoptic bronchoscopy is a very

useful tool—it allows diagnosis by biopsy or bronchial washings and
can detect small lesions.

The bronchoscope is used routinely at some

centers to document complete response to therapy.
CT scans of the chest are less widely used, although they provide
a better sense of tumor volume.

Some note that the CT scan's

sensitivity is not matched by its specificity in detecting malignant
pulmonary nodules when compared to conventional linear
tomography.

Others point to the relative inaccuracy of CT scans in

diagnosing disease in the middle mediastinum when compared to staging
mediastinoscopy or thoracotomy.^

Still, CT provides useful

information not obtained with conventional radiography.

51,52

Both mediastinosocopy and CT of the chest may take on a more
important role in initial staging in the future.

The reason for this

is the resurgence of interest in TNM staging to evaluate adjuvant

24

surgery for early control of intrathoracic tumor mass.

Surgery aside,

data is accumulating that would indicate a survival advantage for
patients with smaller presenting tumors in the chest.
England

53

A group in

found a higher incidence of complete response and a survival

advantage for patients with intrathoracic tumors whose total
cross-sectional was area less than 30 cm

2

on CT.

A Toronto group

54

reported a significant survival advantage for limited disease patients
without superior mediastinal node involvement as diagnosed by
mediastinoscopy or roentgenographic appearance—i.e.,

patients with

so-called "very limited" disease, which is potentially resectable.
These two studies illustrate the potential use of CT and/or
mediastinoscopy in evaluation of chest tumor extent.

Such information

could be useful for treatment and/or prognosis.
Bone and bone marrow are common sites of metastatic spread.

It

seems important to perform both bone marrow biopsy and aspiration^ as
well as bone scan

56

if extent of disease is to be assessed,

procedures complement each other to some extent.

for the

The prognostic
57

significance of these sites of involvement is unclear,

however.

Two

recent studies found bone marrow involvement to be a negative
prognostic factor;
significance. ^

58 59
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a third report found no prognostic

A study from the Finsen Institute^ identified a

group with an especially poor prognosis:
metastases and thrombocytopenia.

patients with bone marrow

In any case, bone scan and bone

marrow biopsy and aspiration remain standard procedures in staging
SCCL.

Ihde and Hansen

48

have reported worsening of the bone scan
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during overall disease remission in a minority of patients.
Liver metastases appear to be a negative prognostic factor.
Groups at the NCI

46 61
59
’
and Toronto
have found liver involvement to

bode ill and the level of interest in accurate diagnosis of liver
metastases supports the wide acceptance of this notion.
A variety of techniques may be used to evaluate the liver,
including liver function tests,
peritoneoscopy with biopsy,
with fine needle aspiration.

percutaneous biopsy, and ultrasonography
Liver-spleen radionuclide scan remains

the mainstay of current staging.
maligned,

radionuclide scanning, CT,

Although this modality has been

it remains a reliable, available,

non-invasive diagnostic tool in SCCL.

62

relatively inexpensive,

At the NCI,

peritoneoscopy

with liver biopsy was found to be the most sensitive diagnostic
method,

but an algorithm combining radionuclide scan with liver

function tests was highly accurate while remaining non-invasive.^
recent study from the Finsen Institute

63

A

reported ultrasonography with

fine needle aspiration to be more accurate than peritoneoscopy.

The

ultrasound technique was also ’’less invasive"—but the number of
patients studied was small.
Whether or not prophylactic irradiation should be employed to
avoid CNS metastases in patients with SCCL is a controversial topic.
Less controversial is the prognostic significance of CNS involvement
and how to diagnose it.
Brain metastases are present in approximately 10% of patients
with SCCL at diagnosis and in 30-65% of patients at autopsy.

48

As
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therapy improves and patients with SCCL live longer,

they accumulate

greater risk for developing this complication.
Both the NCI^ and Toronto"^ groups found brain metastases to be
a negative prognostic factor,
invariable.
head.

but this result has not been

Diagnosis can be made by radionuclide scan or CT of the

CT scans are thought to be superior,^ uncovering lesions

before they become symptomatic and allowing accurate staging.

64

A current set of recommendations for restaging of patients
thought to have achieved clinical response is presented in Table
5.5

The argument that restaging should be effected with as much care

as initial staging is a good one since any metastasis large enough to
be clinically detectable is of great significance.
biomarkers already described (e.g.,

bombesin,

Perhaps someday

neuron-specific enolase)

will become standard indicators of subtler disease.
What factors can be said to have prognostic significance in SCCL?
Performance status—a numerical estimate of a patient's ability to go
about his daily routine with or without symptoms—and stage of disease
(limited vs.

extensive),

prognostic factors.

48 59
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predominate in most studies of significant
In fact,

the International Association for

the Study of Lung Cancer feels it is no longer necessary to
demonstrate the superior survival of patients with LD in current
chemotherapy treatment reports.^

Still,

significantly improved

survival for LD patients is not a universal finding.

4-6

Data already

mentioned indicate that small intrathoracic tumor area and a finding
of "very limited" (i.e.,

potentially resectable) disease may confer a

27

prognostic advantage.

53 54
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Patients who have failed a previous

chemotherapeutic protocol invariably have a bad prognosis on
second-line therapy.

48

The following are of less certain significance.

Weight loss on

presentation (0-10%) has been found to be associated with
significantly decreased median survival,
sites (one vs.

two vs.

three or more).

46
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as has multiple metastatic
Age of 55 years of more has

been associated with decreased response rates and shorter survival in
patients not achieving complete response.^
Numerous laboratory parameters may be useful as prognostic
indicators; carcinoembryonic antigen (CEA) has been reported to be an
independent prognostic factor, ^ as has LDH.~^’^

The feasibility of

using an objective prognostic index based on laboratory parameters at
diagnosis to replace subjective performance status assessment is under
study.

At the NCI, ^ albumin and hemoglobin were found to be the most

influential prognostic factors in survival.
The fact that,

of the various metastatic sites, CNS and liver are

the most likely to have prognostic significance has already been
discussed.
Finally,

the prognostic significance of the various subtypes of

SCCL remains unclear.

The VA Lung Groups reported better survival

for patients with lymphocyte-like (classic,
vs.

intermediate-type disease.

extensive disease group,
analyzed separately.

oat-cell)

This held true for patients within the

but not the limited disease group, when

72
In contrast, a large NCI study ~ found no
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clinically significant differences among the subtypes.

A recent

community hospital study indicates that lymphocyte-like SCCL may be
associated with better 2 year survival.

73a

The pathology panel of the International Association for the
Study of Lung Cancer is in the process of proposing a revision of the
current WHO histological classification system for SCCL.
"combined" subgroup would remain; however,

73b

The

"oat cell" and

"intermediate" subtypes would be classified together in the new
"classic small cell" subgroup.
created;

Another new subgroup would be

"small cell-large cell," in which there is an admixture of

classic small cells with large cells having open nuclei and prominent
eosinophilic nucleoli.
Dr. Raymond Yesner has reported,

in a personal communication,

73 b

that the new classification system is based on the belief that
polygonal and fusiform cell types—currently grouped in the
intermediate subtype—show no significant clinical,
ultrastructural differences from classic oat cells.
study7^ as reported earlier in this paper,
for oat cell over intermediate-type disease.

biological, or
The VA Lung Group

found a survival advantage
It turns out that this

group, unlike investigators who found no such survival advantage,
included in the intermediate subtype only tumors with a mixture of
classic small cells and large cells—not tumors of polygonal and
fusiform cells, which they grouped with classic oat cell tumors.

The

proposed classification system is based on the belief that tumors of
the small cell-large cell subgroup carry a graver prognosis than those
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of the classic small cell subgroup.
Finally, the new small cell-large cell subgroup is thought to be
identical to the in vitro "variant" cell line described earlier in
this paper based on reports from the NCI.
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The variant cell line

is relatively resistant to radiation and chemotherapy and has a large
cell appearance,
Similarly,

but produces some characteristic SCCL biomarkers.

the classic small cell subgroup is felt to have its in

vitro equivalent in the NCI's "classic" subclass.
Table 6 presents a summary of prognostic factors.

PART TWO:

TREATMENT

Overview

A better theoretical grasp of cancer in general now permits
clinicians to treat SCCL with a modest degree of success.
characteristics of the tumor become better understood,
of current therapy become painfully clear.

As the

the limitations

Will the treatment

breakthrough come from the slow evolution of rational therapeutic
design or through a fortuitous discovery?

It is unlikely that

stepwise investigation will cure SCCL in the near future; and,

given

the cost-conscious environment of present-day cancer research, the
prospect of a serendipitous discovery is better thought of as a
fantasy than a hope.
In order to treat SCCL and to evaluate properly its response to
treatment,

the growth characteristics of the tumor need to be known.

Two basic approaches exist:

measures of clinical doubling time made

by estimating tumor volume changes on chest radiographs over time; and
in vitro studies of tumor cells.

Tritiated thymidine uptake by SCCL

cells allows calculation of the labeling index (LI)—the fraction of
labeled tumor cells among all cells counted.

LI reflects the rate of

cell production by the tumor—it measures the fraction of cells
actively synthesizing DNA.
SCCL responds well—initially—to treatment with radiation
therapy

73c

(which acts on dividing cells) and to treatment with agents

such as methotrexate (which is S-phase specific) and cyclophosphamide
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(which is probably cycle-dependent).

74

Intuitively, one would

therefore expect SCCL to be a rapidly dividing tumor—one with a high
LI and short doubling time as measured in clinical studies.
Initial results were consistent with this view.^

For a while,

researchers took a value of about one month as the doubling time of
small cell tumors.

Based on this assumption, the period of risk—the

amount of time for regrowth from a single cell to clinical
recurrence—was thought to be about two years.
Two years became a magical interval,
survival^^ and, perhaps,

cure.

synonymous with long-term

This view was consistent with

clinical impression, doubling time data, and the finding that SCCL had
a higher median LI than other solid tumors (except Burkitt's
lymphoma).

78

Although it has since become clear that two year

survival is of limited value,
criterion.

it remains,

for many, an important

A review article from 1982 states that "many patients who

survive alive and disease-free for 2 years,
disease-free."

79

remain

The reference given, from 1979, was employed

i
77
above.
In 1978, a group at the NCI
77 days (range:

reported a median doubling time of

25-160 days) among their 12 cases of SCCL.

Most

tumors were felt to have demonstrated relatively intermediate or long
doubling times.

Assuming that the range of lxlO^3 to 1x10^ cells is

clinically significant,

the authors used the median doubling time of

77 days to project that therapy leaving a tumor burden of 1x10
would not present as a clinical relapse for at least two years;

cells
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therapy destroying all but one cell would produce an interval of risk
lasting 4-5 years.
The above projections may not be entirely accurate.

First,

range of tumor doubling times must be taken into account.

the

Second,

treatment may change the cell kinetic characteristics of SCCL
tumors;

78

there is good evidence to support biochemical and

histological changes in tumors after therapy.

81 82
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Still,

4 or 5 year

survival is probably more accurately synonymous with long-term
survival if cure is implied.

Clinical evidence has accumulated to

support this notion in the form of late relapses.
Such evidence has been available for a number of years.

The

NCI-International Association for the Study of Lung Cancer report

83

which appeared in 1980 studied patients who survived more than 2.5
years.

Recurrent disease was noted in 21 of 96 patients:

died 30-33 months after diagnosis; one was alive,
months;

8 patients

with disease, at 34

recurrence was detected in 10 other patients after 36-51

months; and two patients treated by surgery alone succumbed to
recurrent disease at 8 and 9 years,
Recently,

respectively.

data from cooperative and single institutions have been

gathered on late relapses.

The NCI

84

reported that 8 of 28 patients

who had been disease-free at 30 months relapsed with SCCL (median:
months from diagnosis;
years.

range:

31-74 months) after follow-up of 5-10

The group at M.D. Anderson Hospital reviewed patients

surviving 3 years or more.
systemically.

Eleven of 43 such patients relapsed

Seven of the 11 relapses were at more than 3

54

33

years.
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Livingston,

86

reporting for the Southwest Oncology Group,

looked at 17 patients who survived 5 years or more in a single study
(13% of those entered).
(onset:

Five late deaths were due to recurrent tumor

33-73 months from treatment).

As early as 1978, Greco et al.
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published a paper in which the

notion that 2 year survival might not represent cure was clearly
expressed.

The existence of "late recurrences" was recognized.

Before discussing treatment modalities:

What is the natural

history of SCCL? The median length of survival of untreated patients
with SCCL is generally quoted as 2-3 months,
disease at presentation.^
Lung Study Group,

47

depending on extent of

One widely quoted study is that of the VA

in which 38 SCCL patients with limited disease

achieved a median survival of 11.7 weeks and 108 patients with
extensive disease achieved a median survival of 5.0 weeks on placebo.
In a cooperative VA study reported by Roswit et al.,

88

placebo-treated SCCL patients with limited disease had a median
survival of more than 16 weeks.
Surgery was one of the first modalities used to treat SCCL.
results were not good.

The

Even apparently resectable lesions were

frequently found to have seeded distant sites;

relapse was the rule.

A study of pathology material from the tumors of 19 patients who died
within 30 days of apparently successful surgical resection found
persistent disease in 13 of 19 patients,
metastases.

89

12 of whom had distant

Radiation therapy (RT) alone proved better than surgery

in a British Medical Research Council trial.
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The patients had

limited disease thought to be resectable and were fit enough for
surgery or radical RT. At 10 year follow-up,
mean survival of 199 days,

the surgery group had a

the RT group 300 days.

Three patients in

the RT group who survived five years remained alive and disease-free
at 10 years.

Four RT patients died between 2 and 5 years.

The sole 5

year survivor in the surgery group in fact underwent no surgical
treatment due to breathlessness and received RT instead.
In contrast,

in a cooperative VA study already mentioned,
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there

was no significant increase in survival for a group with limited
disease receiving 4-5,000 rads of RT compared to a placebo group.
Median survival for the RT group was a bit over 16 weeks.
Selawry,
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in a 1973 report,

single agent chemotherapy.

reviewed the response of SCCL to

Small cell was found to be the most

responsive to single agents of all lung cancer subtypes.
Therapeutic design moved quickly once the efficacy of
chemotherapy had been shown.
chemotherapy,

Radiation therapy was combined with

creating a multi-modal approach;

chemotherapeutic agents were employed.

87 92
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multiple

It became clear that

patients who achieved complete response lived longer than those
achieving partial response or no response (in complete responders,

the

disease had been made clinically undetectable); and partial responders
seemed to live longer than non-responders.
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Chemotherapy has become the backbone of therapeutic approaches to
SCCL.

Basic principles of chemotherapy design have been applied to

the disease.

Attempts have been made to:

combine drugs which have
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therapeutic efficacy as single agents; choose combinations of drugs
with different modes of action; treat with apparently non-crossresistant sequential combinations of drugs;

find combinations of drugs

with synergistic anti-tumor effects; and use drug dosages high enough
to maximize dose-response advantages while minimizing the inherent
trade-off of dose-related toxicity.
Disease extent is a major prognostic factor in SCCL and treatment
results reflect this fact.

It is wise to discuss therapy of limited

disease and extensive disease separately.

In general, limited disease

treatment has changed little in the past five years and is dominated
by controversies over the use of radiation therapy to the chest and
prophylactic cranial irradiation as adjuvants to combination
chemotherapy.

An exception to this statement is the renewed interest

in surgery as an adjuvant therapy in resectable lesions.
creative approaches to therapy—new drugs,

The more

larger doses,

non-cross-resistant sequential combinations—have been confined
largely to treatment of extensive disease or patients who have
relapsed.

The reason for this is that current conservative

therapeutic designs produce a predictable, although small, number of
long-term survivors in the limited disease group;

the extensive

disease group has fewer responders and shorter survival.
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Clinicians

are reluctant to give up "acceptable" survival and known toxicity
risks for experimental therapies.
Aisner et al.,
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reporting for the International Association for

the Study of Lung Cancer have summarized current expectations in
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trials employing aggressive therapy against SCCL.

Combination

chemotherapy should produce complete response in more than 50% of
patients with limited disease (LD) and more than 20% of patients with
extensive disease (ED).

With adequate staging, median survival of at

least 14 months in LD and 7 months in ED may be expected.

Finally,

15-20% of LD patients should achieve disease-free survival of 3 years
or more although such survivors remain rare among ED patients.
Table 7 presents a summary of selected treatment protocols for
SCCL.

It is intended to show the evolution of therapy and variability

of treatment results.

It does not present highly experimental

approaches of the kind usually reserved for extensive disease patients
or patients who have relapsed from first-line therapy.
from the same paper,

Unless drawn

the studies are not comparable.

Table 8 presents information on long-term survivors from studies
using various treatment modalities.

Treatment of Limited-Stage Disease and
Treatment-Related Toxicities

Two controversial aspects of therapy design are especially
relevant to limited disease,
effective local control:

since their goal is prophylaxis or rapid,

the use of prophylactic cranial irradiation

(PCI); and intrathoracic irradiation for local tumor control,
adjuvants to combination chemotherapy.
Neither non-randomized nor randomized trials of PCI have
demonstrated any clear advantage in survival.

99,103

both as
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Baglan and Marks
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thus argued that the nominal purpose of PCI

was to prevent neurological signs and symptoms,

since their review of

the literature uncovered an incidence of brain metastases averaging
23% for patients not receiving PCI versus 5% for the PCI group.

The

authors were able to treat 64% of 39 patients with brain metastases
(all but 4 of whom were symptomatic) successfully enough to eradicate
symptoms for the rest of the patients'
that,

lives.

The authors predicted

based on their results treating symptomatic patients and on

previous treatment results with PCI,

of 100 prophylactically

irradiated and 100 symptomatically irradiated patients,

77 extra

patients would have to receive PCI so that 3 patients might be spared
CNS symptoms.

They considered the potential benefit of PCI to be

insignificant.
Baglan and Marks's argument hinges on effective treatment of CNS
metastases.

Agreement on this point is not uniform;still, a

recent NCI study indicated that brain metastases can be treated
effectively enough so that such patients die of other causes in most
cases.
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A large retrospective NCI study^^ examined PCI with a special
interest in:

PCI timing; PCI's effect on long-term survival; and

selection of any subgroups of patients for whom PCI would be most
helpful.

The results were of great interest:

there was significant

improvement in overall survival for the group receiving PCI. However,
the group which received no PCI also had the least intensive
chemotherapy.

With that caveat in mind,

the authors felt that PCI had
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its greatest positive effect in the complete responders (with limited
or extensive disease).
had received no PCI,

Among patients achieving complete response who

17% relapsed in a CNS site alone.

Isolated CNS

relapse was seen in no complete responders who had received PCI. Two
and three year survival was improved in the PCI groups,
significantly so.

With respect to the timing of PCI:

but not
there were no

CNS relapses in the first four months in any group and no striking
treatment result differences between a group receiving PCI on day 1 of
the protocol and a group receiving PCI at week 12 or 24,

contingent on

a complete or partial therapy response.
The NCI group thus suggested that PCI may be most effectively
employed at 2-4 months,
achieved.

after documented complete response has been

Patients achieving less than complete response could be

treated symptomatically since the study found no apparent advantage
using PCI in that group.

A recent study from Toronto
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found no

increased survival but significantly decreased brain relapse at 2
years for complete responders receiving PCI (21% vs.

52%).

Data is accumulating to support selective use of PCI—the data is
on toxicities associated with PCI. Numerous groups have reported
neurological toxicities among long-term survivors which may be due to
PCI or the combination of PCI and chemotherapy (nitrosureas,
.
x 84,104,105
particular).

in

.
T
j,
.
106 ,
A group at Indiana University
found

neurologic problems in 9 of 11 long-term disease free patients (>3
years) who had received PCI + nitrosureas, and in 6 of 8 patients who
had received PCI and chemotherapy without nitrosureas.

Onset of
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neurological symptoms was usually 1-3 years after completion of
therapy.

Problems encountered included memory loss,

confusion, ataxia,
atrophy.

psychomotor retardation,

dementia,

dysphonia and optic

Two patients required institutionalization; 6 others have

had great impairment of their daily lives.
had no neurologic impairment after therapy.

Only 4 of 18 patients have
Recently,

a prospective

evaluation revealed an '’extraordinary high frequency of CCT
(computerized cranial tomography) abnormalities in patients with SCCL
after treatment with chemotherapy and cranial irradiation...."^^
The role of PCI in the treatment of SCCL remains unclear.

It

appears that PCI may offer a relapse protection advantage in patients
achieving a complete response that is worth the risk of possible
long-term neurological side effects.

Much may depend on the side

effects clinicians are willing to tolerate to protect the subgroup of
complete responders who, without PCI, would experience isolated CNS
relapse.

Neurological side effects need to be further studied so that

especially toxic PCI-chemotherapy combinations can be avoided.
data are needed on survival,

More

relapse, and toxicity through randomized

trials of PCI in complete responders.
The controversy surrounding the use of radiation therapy to the
chest to complement multi-agent chemotherapy is a complex one.
Multi-modal therapy,
chemotherapy,

referring to combined radiation and

is of two main types:

sequential therapy,

sequential and concurrent.

there is a temporal pause between the two

modalities; in concurrent therapy,

they are given simultaneously.

In
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I QO

Catane et al.,

found a trend favoring concurrent therapy over

sequential therapy for increased two year survival.
was not statistically significant,

however.

The difference

The concurrent therapy

group achieved better complete therapy response with local tumor
control and,

of patients achieving complete response,

fewer patients

receiving concurrent therapy relapsed in the radiation therapy
portal.
The toxicity enhancement effects of concurrent therapy are
critical in evaluation of protocol design.

In Catane's study,

7 of 14

patients receiving maximal concurrent radiation and chemotherapy (9
weeks) died of treatment toxicity.

Yet,

4 of the 7 treatment

survivors achieved 2 year survival—the highest proportion of any
group in the study.

The authors concluded that 3 weeks of concurrent

radiation therapy (RT) and chemotherapy (CT) produced the optimal
combination of high 2 year survival and acceptable toxicity.
Cox et al.,
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found that tumor control probability, assessed by

serial chest radiographs,

increased with increasing biological dose in

patients treated with RT alone.

But in RT + CT patients,

local

control was achieved at lower RT doses than would have been expected.
RT was generally begun during the last week or immediately after
completion of chemotherapy.
The point is that RT and CT appear to act synergistically:

they

enhance each other's treatment effects but they also enhance
toxicities.
pulmonary,

Acute toxicity enhancement effects include myocardial,
skin and esophageal damage with Adriamycin;

chronic
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toxicities will be discussed shortly.

However,

delay of one week

between modalities is thought to be protective.
We enter the RT + CT vs. CT alone controversy with this
perspective:

the timing of combined modality treatment is important

for toxicity and anti-tumor effects;
with CT on tumor cells.

To date,

RT seems to act synergistically

the critical parameters of RT-CT

combination therapy—timing and dosage—have not been adequately

,

studied.
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The main argument for combined modality treatment is local tumor
control.

Byhardt and Cox

112

argue that failure of chemotherapy alone

to prevent relapses in the chest is the reason to add adjuvant RT.
Combined modality therapy reduces relapses in the radiation portal
and, with this local tumor control,

allows better long-term survival

for limited disease patients.
Cohen
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notes that the true test of adjuvant RT is whether or

not it increases the number of long-term survivors—i.e.,

patients

living at least three years—in randomized trials comparing RT + CT to
CT alone.
The use of adjuvant RT in extensive disease is not as
controversial a topic.

Most investigators seem to agree that survival

is not increased by RT to the primary tumor.
notion are relatively scanty,
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The data supporting this

but meticulous local control

apparently strikes most investigators as less essential when the tumor
has already spread beyond one hemithorax.

What can be said about

local control and its relationship to long-term survival?
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Peschel et

in a retrospective review of 12 patients

achieving survival of more than 2 years,

stressed the need for local

tumor control—surgery or high dose (>4800 rads) lung irradiation—to
avoid local relapse.

Three of 5 patients who had received

chemotherapy alone or low dose irradiation (<3500 rads) had late local
relapses.

Similarly, Matthews et al.

83

reported on the treatment

received by patients in their long term (>2.5 year) survival
registry.

The two largest groups represented were patients who had

received RT + CT and those who had received surgery alone.

(The role

of adjuvant surgery in current treatment protocols will be discussed
later.)
Several controlled,
CT alone.

Hansen et al.

randomized studies have compared CT + RT to
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reported shorter median survival in the RT

+ CT group compared to the CT group.
Perez et al.
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reported better median survival and complete response

rate with thoracic irradiation.
initial,

The Perez study also reported an

significant superiority in actuarial 3 year survival for the

group receiving RT (20% vs.
group.

In contrast, Bunn et al3^ and

5%).

Toxicity was greater in the RT + CT

There were 2 induction deaths in the RT + CT group vs.

the CT group in Bunn's study.

Mira et al.

day 85 of their protocol and found that,
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none in

have added RT to CT at

in about 1/3 of responders

who did not achieve complete response after initial CT, RT increased
complete response rate and median survival.
Radiation therapy to the chest has a logical place in the care of
patients with limited-stage disease.

Local control is an extremely
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useful concept in designing treatment protocols for long-term
survival.

Still,

the trade-off is increased toxicity.

This is a good point to review treatment toxicities briefly, with
a special interest in toxicities associated with combined modality
therapy.

120 121a
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Most chemotherapy regimens used for treating SCCL

produce some degree of myelosuppression.

Addition of radiation

affects the bone marrow and in a healthy adult,

ribs,

sternum, and

121b

scapula comprise 15-20% of functioning bone marrow. “

With most

standard CT protocols the duration of granulocytopenia is relatively
short; febrile episodes are reported in about 30% of patients,
documented infections in 5%,

fatal infections in 2%.

When adjuvant RT

is added, infections have been reported to rise to 11.7%,
infections to 2.7%.

120

fatal

Infection can be documented in about 40% of

febrile, neutropenic patients; 50% of these have bacteremia.

A total

of 60% of febrile, neutropenic patients are thought to be infected on
the basis of cultures or clinical signs or symptoms.

120

Thus,

antimicrobial therapy is empirically employed in all such patients.
Radiation therapy alone—but especially in combination with
chemotherapy—contributes to two major acute toxicities:

esophagitis

and pneumonitis.
As has been mentioned, Adriamycin enhances radiation induced
esophagitis.

Chronic esophageal stricture is a hazard avoided through

careful planning of the portals and timing of RT and of the dose and
type of cytotoxic therapy.
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CT adds to the problem of radiation pneumonitis; also,

chronic

pulmonary fibrosis has emerged as a major concern in long-term
survivors after multi-modal therapy 5^
Cardiac toxicity is a potential complication of SCCL treatment.
Pericarditis, aggravation of coronary artery disease, and
cardiomyopathies especially associated with Adriamycin are all
potential toxicities.
Peripheral neuropathy is a toxicity associated with vincristine.
The long-term neurological sequelae of CT + RT have already been
discussed in the context of prophylactic cranial irradiation.
Finally,

second malignancies are arising as toxic complications.

Four cases of acute leukemia—all arising 2-1/2 to 3 years after
diagnosis of SCCL—have been reviewed by Abeloff et al.
patients had achieved complete responses;
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All four

3 of the 4 had received

multi-modal CT + RT therapy.
Adjuvant surgery is a final topic to discuss in the treatment of
limited-stage SCCL.

Two studies have been mentioned which examined

the characteristics of long-term survivors with SCCL;
study,

83 115
’
in each

patients who had received surgery as initial or only treatment

formed a significant subgroup.
The role of adjuvant surgery remains unclear.
contributed a relatively early study,
updated.
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Comis et al.
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which they have recently

TNM staging was used for the surgical procedure;

the

authors found that patients with superior mediastinal (N2) disease did
not seem to benefit from adjuvant surgery.

Foster et al.

124

found
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that—due to extent of disease or such factors as poor medical
condition and inadequate pulmonary function—only 10 of 37 eligible
limited disease patients were surgical candidates.
in a retrospective review,

Friess et al.,

125

found that the 15 patients with limited

disease who had entered one of their combined modality protocols after
surgical resection had significantly better median and 2 year survival
than patients without initial surgery.

The best median survival was

in patients with the smallest lesions (<5 cm) who had undergone
surgery before starting the protocol.
Adjuvant surgery in SCCL may become an accepted treatment
modality.

Comis et al.

122

have some good initial results,

number of patients is very small.
adjuvant surgery most effective?
or after initial chemotherapy?)

but the

Basic questions remain.
(I.e.,

When is

should it be employed before

Is adjuvant surgery only possible or

efficacious in a relatively small number of patients?

Finally:

are

the results of adjuvant surgery going to reflect better treatment or
simply the better prognosis of a subgroup of patients with "very
limited" stage disease?^

Extensive-Stage Disease and Experimental Therapies

Comis,

114

in his review of treatment for SCCL,

considers

infrequent long-term survival to be the distinguishing characteristic
of extensive-stage disease.
toxicity; multiple,

Intensive therapies (high dose,

high

novel combinations; new drugs) have achieved

better median survival.

A glance at the registry of long-term
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OO

survivors

(>2.5 years) reported in 1980 reveals that,

patients, only 8 presented with extensive-stage disease.

of 97
Extent of

disease is a powerful prognostic indicator and survival data reflect
this fact.
Comis

114

cites the following as the most prevalent new approaches

to extensive disease:

increasing the intensity of chemotherapy; using

a sequence of drug combinations which are thought to be
non-cross-resistant; and incorporating Etoposide (VP-16-213) into the
initial combination of drugs.
Intensive chemotherapy seeks to take advantage of dose-response
relationships and of the intuitive notion that if "effective" is good
"intensive" is better.

Aisner et al.

on dose schedule dependency.
proceeds slowly,
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point to the paucity of data

The determination of maximum doses

on a drug-by-drug basis.

appears to be the end-point.

Maximum acceptable toxicity

The results have not been encouraging

and toxicity risks are considerable.

Late intensive combined modality

therapy with autologous bone marrow infusion
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and high-dose therapy

with protected environment-prophylactic antibiotic units to reduce
infectious morbidity

127

have been reported to yield no long-term

survival advantage over more conventional therapy.
infection are prominent risks.

Neutropenia and

High dose regimens may be especially

beneficial in patients achieving complete response;^however,
generally low rate of complete response among extensive disease
patients limits their potential application.

the
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Another novel approach to therapy is the use of
non-cross-resistant drug combinations in cycles.
been exciting;
Evans et al.
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’
still,
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The results have not

the approach may hold some promise.

have pointed out that most alternating sequences of

drugs do not appear to be truly non-cross-resistant.
truly

They cite a

non-cross resistant sequence study in which response was

improved.
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Still,

"truly non-cross-resistant" seems to mean that

potentially better response is achieved by achieving potentially
better response—a suspiciously circular chain of reasoning.
New drug development is,
research.

These drugs,

of course, a major focus of continuing

for ethical reasons, are usually tested

initially in patients for whom first-line chemotherapy has failed.
Aisner et al.^ note the hazards of this approach.

It may be that

aggressive initial therapy alters the nature of the tumor so that it
becomes refractory to any subsequent treatment.

(Evidence that

therapy changes biochemical and histological characteristics of SCCL
tumors has already been noted in this paper.
Etoposide and vindesine as examples.
active single agent in untreated SCCL,
over 40%.
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Yet,

81 82
’
)

Aisner cites

Etoposide is probably the most
with response rates averaging

the drug has generally been found to produce

insignificant response rates in patients refractory to standard
therapy.
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Perhaps the problem is not pre-treatment,

but simply that

tumors unresponsive to first-line therapy are refractory to most novel
therapies as well.

48

In any case, Etoposide (VP-16-213) has proved to be a promising
new agent in treating SCCL.

It appears to show a dose-response

relationship; a study of high-dose Etoposide achieved an 80% response
rate in 10 patients with extensive disease.
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Etoposide is often

used in current multi-agent chemotherapy combinations.
VM-26 (related to vincristine),
"logically,M vindesine + Etoposide
SCCL.
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vindesine,

13A 133
’
and,

may have activity against

The latter seems a good example of combining two drugs to see

if the combination proves to have some magical synergism.
synergism is found.

Sometimes

When Etoposide alone was compared to Etoposide +

cis-platin (EP) in patients refractory to cyclophosphamideAdriamycin—vincristine (CAV) therapy
better response rate,
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,

the EP group experienced a

higher median survival and increased

thrombocytopenia all thought to reflect the synergistic action of
Etoposide and cis-platin described in some animal tumor
systems.
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Since their patients had been refractory to CAV therapy,

the authors suggested they may have found a truly non-cross-resistant
sequence for further investigation (CAV-EP). The usefulness of EP as
consolidation therapy after initial CAV or "combined alkylators" has
been reported to show little promise.
Finally, mention should be made of two studies similar to the
Yale treatment protocol for SCCL whose results appear in the next
section of this paper.

Zekan et al.
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found that CAVE afforded

significantly increased total treatment response over CAV (82%
vs. 66%).

Etoposide was said to have added little toxicity although
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3/57 CAVE patients suffered treatment-related deaths vs.
patients.

1/59 CAV

Estimated median survival was not significantly different

for the two treatment groups in limited disease or extensive disease.
Messeih et al.
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response rate (65% vs.

reported a significantly increased overall
50%),

and complete response rate (44% vs.

18%)

for their CAVE group and—strikingly—extensive disease patients
achieved a complete response rate of 35% on CAVE versus 0% on CAV.
Overall median survival for all responders and median survival for
complete responders was not significantly different for the two
treatment groups.

Closing Comments

Despite the tantalizing response of SCCL to initial radiation or
chemotherapy,

relapse is the rule.

Long-term survival (best defined

as longer than 4-5 years if any association with cure is to be
implied) is rare.

Extensive disease patients have an especially

dismal prognosis but this may improve if more can achieve complete
response to therapy.

Still,

the disease remains one in which many

patients are treated to allow survival of a few.
toxicities can be avoided with rational dosage,
of therapeutic modalities.

Severe treatment
timing, and selection

They should be avoided,

for there is no

evidence that toxic therapies are the best therapies,

and when cure is

rare treatment should be relatively palatable.
Limited-stage disease offers the most hope.

Prophylactic cranial

irradiation (PCI) appears to have enough chronic neurological
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toxicities that its use is best limited to complete responders,
four months after the start of therapy.
mostly in limited-stage disease.
if,

for example,

two to

Thus, PCI will be employed

PCI may fall out of favor entirely

its chronic toxicities are found to outweigh its

protection of the subgroup of patients who would otherwise suffer
isolated CNS relapse.

Nitrosureas appear to be especially associated

with the chronic toxicity of PCI. Patients with less than complete
responses can be treated for CNS metastases as they arise.

Chest

irradiation makes a great deal of sense in limited disease;

there is

enough clinical evidence and good theoretical speculation to support
the notion that local control of intrathoracic disease is essential
for long-term survival.

Care must be taken to avoid acute toxicities

that accompany multi-modal therapy;

chronic pulmonary toxicity is a

significant factor which requires further study.
The importance of local control makes adjuvant surgery a
potentially useful treatment modality.

The apparently superior

survival of patients with small "very limited" tumors highlights the
need for a biochemical marker or other method of early diagnosis
before SCCL becomes clinically apparent.
could be screened for the disease,
improve,

If high risk populations

survival in SCCL would certainly

even with the limitations of current therapy.

Our understanding of SCCL is poor.

The variability of treatment

results and the resistance of small cell tumors to second-line drugs
are but two reflections of our ignorance in the clinical setting.

The

variability among pathologists in identifying tumor subtypes and the
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lack of apparent prognostic significance of these subtypes make the
current system of histological classification questionable.
Heterogeneity is the hallmark of SCCL:
in chromosome number,
clonal origin,

tumor cells are variable

proliferative activity, antigenic expression,

cytomorphology and biochemical behavior (including

expression of tumor products and biochemical markers).
with few or no neurosecretory granules,

Tumor cells

low dopa decarboxylase and

bombesin activity, high ploidy and active proliferative behavior have
all been identified as belonging to a clinically more aggressive
subclasss.

The "variant" subclass of tumor cells may be both

radioresistant and more aggressive than the "classic" subclass.

The

origin of aggressive tumor cells is obscure since dopa decarboxylase
and neurosecretory granules are distinguishing APUD characteristics.
Perhaps they evolve from cells in the original tumor (i.e., the tumor
formed by initial malignant transformation).
The reclassification of SCCL proposed by the pathology panel of
the International Association for the Study of Lung Cancer is of great
significance.

It is thought that the NCI's "variant" subclass tumor

cells are the _in_ vitro equivalent of the proposed small cell-large
cell subgroup, and that the NCI's "classic" cells are the in vitro
equivalent of the proposed classic small cell subgroup.

If,

for the

first time, a prognostically significant classification system has
been found, whose subtypes can be reliably identified by different
pathologists and studied with equivalent in vitro cell lines,

then a

major step will have been taken in the struggle to link basic science
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research on cellular characteristics with clinical practice.

Until

then, information on the heterogeneity of SCCL tumor cells and the
cellular characteristics of clinically aggressive tumors goes beyond
our ability to use it:

the information doesn't help in diagnosis,

our diagnostic tools detect only gross disease;

for

it doesn't clarify our

histological classification system, which is based on light
microscopy; it doesn't assist us in prognosis, which is based on gross
extent of disease and subjective evaluation of a patient's ability to
carry out his daily tasks; and it probably won't help us design better
therapy, since our therapeutic modalities are so very limited.
only work on cells will characterize the SCCL tumor.

But

Our methods of

diagnosis, classification, prognosis, and treatment will become more
refined as understanding of the tumor cells expands.

New

modalities—hyperthermia, monoclonal antibodies, radiosensitizing
drugs^—may prove useful by empirical trial.

Today's dilemma is that

a hit-or-miss approach to SCCL is bound to fail and the information we
need for rational therapy is elusively basic.
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PART THREE:

THE STUDY

This paper presents the initial results of a Yale University
treatment protocol for small cell cancer of the lung (SCCL).
are part of a continuing study; methods,

patients,

The data

results, and

discussion are presented below.

Methods

During the period October,

1980 to April,

1983 all referred

patients with histologically confirmed SCCL (by cytology or biopsy of
metastatic sites) were entered in the study.
regardless of stage of disease,
expectancy,

Patients were accepted

performance status,

or life

provided they had at least one site of measureable or

evaluable disease.

Patients were ineligible for inclusion in the

study if they had received prior treatment for their disease,
exception of surgery,

with the

or if their left ventricular ejection fraction,

by gated blood pool scan, was too low to permit treatment with
Adriamycin (doxorubicin).
Pretreatment staging evaluation included history and physical
examination with evaluation of performance status.
included CBC,

platelet count,

BUN,

creatinine,

(total/direct), alkaline phosphatase,

glucose,

prothrombin time/partial thromboplastin time,
for ectopic hormones as indicated.

Blood tests

bilirubin
electrolytes,
cortisol,

and studies
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Diagnostic procedures included bone marrow biopsy and aspirate;
chest x-ray with tomography in all patients with limited-stage disease
and others as indicated; liver-spleen scan and bone radionuclide
scans; CT scan of the head; skin tests for SKSD, PPD,

Candida, mumps;

electrocardiogram; and left ventricular ejection fraction gated blood
pool scan.
Patients were defined as having limited-stage disease (LD) if the
disease was confined to one hemithorax, with or without involvement of
hilar, mediastinal and ipsilateral supraclavicular lymph nodes.
Extensive-stage disease (ED) was defined as disease beyond these
confines.
For treatment,

patients were randomized prospectively to CAV

(cyclophosphamide, Adriamycin,
Etoposide (VP-16-213).

vincristine) or CAV/E (the above plus

Drug dosages were:

cyclophosphamide 1000 mg/m

2

2

Adriamycin 40 mg/m";

2

IV; vincristine 1.4 mg/m" IV (not to

2
exceed a total dose of 2 mg); Etoposide 125 mg/m" IV. CAV cycles were
every 21 days.

CAV/E cycles were every 42 days,

with CAV given on day

2
1,

Etoposide 125 mg/m" IV on each of days 21,

23, and 25,

beginning

again with CAV on day 42.
In limited disease,
primary tumor,
rads per day,
initially.

3000 rads of radiation therapy (RT) to the

mediastinum,

and bilateral supraclavicular nodes as 300

5 treatments per week (10 treatments total) was given

Vincristine and cyclophosphamide in the doses above were

given after staging,

concurrent with the first phase of RT,

by 4 cycles of CAV or 2 cycles of CAV/E.

followed

Adriamycin-containing
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combination therapy thus began after completion of the first phase of
RT and at least 21 days after initial cyclophosphamide and
vincristine.

An additional 2400 rads of RT to the primary sites, with

concurrent cyclophosphamide and vincristine, were given as 8
treatments of 300 rads each,
cycles of CAV/E,

after the first 4 cycles of CAV or 2

before completing 6 more cycles of CAV or 3 more

cycles of CAV/E.
In extensive disease, treatment was as above,

except irradiation

of the primary site was at the option of the responsible clinician.
After cycle 4 of CAV or cycle 2 of CAV/E, all complete responders
with no known brain metastases received prophylactic whole brain
irradiation as 3000 rads over 2 weeks at 300 rads per treatment,
regardless of disease extent at presentation.
Treatment was continued to 10 cycles of CAV or 5 cycles of CAV/E.
See Tables 9 and 10 for summaries of the treatment protocols.
If, after 6-8 weeks of chemotherapy,
progression,

there was disease

patients were considered off-study and treatment was

individualized.

Otherwise,

patients were treated per protocol until

clear-cut evidence of progression or relapse.

Subsequent therapy was

individualized.
At the conclusion of therapy,

patients were restaged to document

response.
Dose attenuations were guided by CBC prior to therapy.
Complete response was defined as total disappearance of all
disease with biopsy confirmation (e.g.,

for bone marrow or liver)
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lasting at least 30 days.
Partial response was defined as a 50% decrease in the product of
2 tumor diameters perpendicular to one another, without associated
progression of any other lesions or the appearance of a new lesion.
Regression had to last a minimum of 60 days.
Stable disease was defined as less than 50% regression of
measureable lesions with the appearance of no new lesions and no
deterioration of performance status.
Progression of disease was defined as the appearance of any new
lesion or the increase in size of any measureable lesion by greater
than 50%.
In this report,

patients with stable disease and progressive

disease are grouped together as "non-responders."
EC0G toxicity criteria were used as a basis for patient
comparison.
Performance status was defined as follows:

0-asymptomatic;

1-fully ambulatory with symptoms; 2-bedridden less than 50% of the
time;

3-bedridden 50% of the time or more;

4-100% bedridden.

Statistical analysis of time to relapse and survival was
performed using Kaplan-Meier plots;

comparisons were made using the

generalized Wilcoxon (Breslow) test of statistics.

All median values

are from the Kaplan-Meier plots and therefore may be projections.
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Patients and Results

Of the 47 patients entered into the study,

8 were inevaluable.

Five of the 8 patients had extensive disease (ED).

Of these 5:

2

patients never got Adriamycin due to inadequate pre-treatment cardiac
function;

1 had intercurrent prostatic cancer;

1 chose to leave the

care of a physician participating in the study after one visit,

for

unknown reasons; and 1 patient had a sudden cardiac death 48 hours
after her only cycle of CAV therapy.
Three of the 8 inevaluable patients had limited disease (LD).
Of these 3:

1 patient had not been on-study long enough to evaluate

response—in addition,

this patient's tumor was of mixed small

cell/large cell histology;

1 had intercurrent prostate cancer; and 1

patient's chemotherapy was discontinued at the patient's request when
symptoms of congestive heart failure developed after one dose each of
cyclophosphamide and vincristine (the cycle contained no Adriamycin).
On-study time was defined as the date treatment started to the
date last seen or date of death.

The 39 evaluable patients had a

median on-study time of 219 days (range 6-907 days).
Twenty-eight of 39 patients have relapsed.
have not relapsed,

Eleven of 39 patients

one of whom died without apparent relapse (of

infection or radiation pneumonitis, as will be described later);
other ten patients are still living and are disease-free.
39 patients are still alive,

including 6 who have relapsed.

the

Sixteen of
The

median follow-up for patients still alive is 219 days (two shortest
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follow-ups:

70 and 97 days;

two longest:

674 and 907 days).

Patient characteristics are presented in Table 11, subdivided by
extent of disease and treatment arm.
limited disease (LD).

Fifteen of 39 patients (38%) had

Twenty-four of 39 (62%) had extensive disease

(ED). Two ED patients presented with superior vena cava syndrome;
patient had SIADH on presentation.

1 ED

One LD patient had significant

non-neoplastic disease on presentation (diffuse scleroderma;

she is

the only patient whose initial performance status is unknown).
As expected, LD patients had better initial performance status
than ED patients (LD—11 of 15 patients fully ambulatory (performance
status 0 or 1); ED—11 of 24 patients fully ambulatory).
was slightly younger than the ED group (median ages:
ED-63.5 years).

The LD group

LD-60 years;

The LD group contained a greater proportion of women

(LD- 9 women:6 men; ED- 11 women:13 men).
Comparing treatment arm groups (Table 11):
group contained younger patients (median ages:
years).

the CAV

CAV-59 years; CAV/E-66

LD-ED distribution was similar for both treatment groups:

21 CAV patients,
patients,

On the whole,

of

there were 8 LD (38%) and 13 ED (62%); of 18 CAV/E

there were 7 LD (39%),

11 ED (61%).

Fourteen of 21 CAV patients (67%) were fully ambulatory
(performance status 0 or 1) versus 8 of 18 CAV/E patients (44%).

Most

of this difference can be accounted for by the fact that 8 of 13
patients (62%) in the ED-CAV group were fully ambulatory versus 3 of
11 patients (27%) in the ED-CAV/E group.
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The CAV/E group contained a greater proportion of women (CAV/E10 women:8 men; CAV- 10 women:11 men).
Three patients had surgery before beginning the protocol:
1 ED.

2 LD,

Patient characteristics are continued in Tables 12 and 13.
Eighteen of 24 ED patients presented with metastatic disease in

more than one site.

Sites of presenting metastases,

by treatment arm,

with the number and percentage of patients presenting with them are
shown in Table 12.

Six of 24 ED patients presented with metastatic

disease involving single sites (see Table 12).
Sites of relapse among all 39 patients (ED + LD) with the number
and percentage of patients relapsing at those sites are presented in
Table 13.

There were 10 relapses in sites of initial disease,

excluding the chest (see Table 13).
Of the 5 brain relapses, 4 occurred in ED patients who had
received no prophylactic cranial irradiation (PCI).

Three of these 4

patients received no CT scan or radionuclide brain scan on diagnosis.
One of the 5 brain relapses occurred in an LD patient with negative CT
scan on diagnosis who relapsed 4 months after 3000 rads of PCI.

The

ED patient who experienced a choroidal relapse had no PCI.
Two LD patients deserve special mention.
palpable subcutaneous nodule at diagnosis,
relapsed in the same site;

The first patient had a

refused biopsy, and later

the second had a radionuclide scan

equivocal for liver involvement at diagnosis and later relapsed in
liver,

bone and bone marrow.
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Nine patients had chest relapses.
received no thoracic irradiation.

Five of the 9 had ED and

It is not known whether the

remaining 4 patients (2 LD; 2 ED) relapsed within their radiation
therapy portals.
Response to therapy, grouped by disease extent and treatment arm,
is presented in Table 14. Objective responses (CR + PR) occurred in 28
of all 39 patients (72%);

in 13 of 15 LD patients (87%);

15 of 24 ED

patients (63%); 8 of 8 LD-CAV patients (100%); 5 of 7 LD-CAV/E
patients (71%); 9 of 13 ED-CAV patients (69%); and 6 of 11 ED-CAV/E
patients (55%).
The following sections present data from Kaplan-Meier curves for
time to relapse and survival.

Subgrouping was performed in analyzing

the data by treatment group (e.g., LD-CAV responders vs. LD-CAV/E
responders); such subgrouping is intended only to reflect the
distribution of the data,

since the small number of patients in these

subgroups precludes in-depth analysis.
Time to relapse was defined as the date treatment began to the
date of disease progression.

The data are presented in Table 14 and

Figures 1-4.
Median time to relapse was 361 days in responders (CR + PR) with
LD; for ED responders,

the median was 188 days.

Analysis of these

relapse curves showed a significantly longer time to relapse for the
LD responders (_p=.0001).

(See Figure 1.)

Time to relapse for ED

non-responders (median:

71 days) was significantly shorter than for

ED responders (2,= .006).

(See Figure 2.)
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Time to relapse was studied by treatment group.
with LD,

time to relapse on CAV (median:

For patients

334 days) versus time to

relapse on CAV/E (median:

361 days) was not significant

(£=•55).

In contrast,

(See Figure 3.)

patients on CAV (median:
(median:
4. )

time to relapse for all ED

193 days) compared to ED patients on CAV/E

109 days) was barely significant (£=.04).

(See Figure

Further subgrouping revealed that time to relapse of ED

responders (CR + PR) on CAV versus those on CAV/E was not significant
(_gj=. 77);

but comparison of ED non-responders on CAV versus ED

non-responders on CAV/E was significant (£=.02).
Survival data,

the main criteria by which protocols are

evaluated, are presented in Table 15 and Figures 5-9.
Median survival for all patients was 301 days.
5. )

(See Figure

Median survival for LD complete responders was 560 days.
Survival of LD responders (CR + PR) (median:

compared to survival of ED responders (median:
be significant (£=.0007).

(See Figure 6.)

versus ED non-responders (median:
(£=.24).

560 days) was

230 days) and found to

Survival of ED responders

198 days) was not significant

(See Figure 7.)

Survival by treatment group was analyzed.
patients on CAV (median:
CAV/E (median:

When survival of LD

560 days) was compared to LD patients on

424 days), no significant difference was found

(£=.24).

(See Figure 8.)

Survival of ED patients on CAV

(median:

230 days) versus ED patients on CAV/E (median:

was not significant (£=.23).

(See Figure 9.)

186 days)
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A glance at the survival curve for all patients shows a plateau
at about 6%.

(See Figure 5.)

plateaus at 35%.

The curve for LD complete responders

But 8 of the 12 patients in this group were still

alive and those 8 had a median follow-up of only 305 days, while
projected median survival was 560 days.
Thusfar,

4 patients have lived 1-1/2 years or more.

Two are

described in some detail below because they will be mentioned in the
discussion of treatment results later on.
First,

a male patient presented at 51 years of age with

performance status 1 and extensive disease—bone involvement,

pleural

effusion of unknown cytology, a subcutaneous nodule in the left flank
and a supra-clavicular node.

After 4 cycles of therapy,

disease had not changed significantly; however,

his chest

he experienced a

choroidal relapse in the left eye, with detachment and uplifting of
the retina.

The patient received radiation therapy to the eye and

additional cycles of CAV. His chest x-ray showed no significant
improvement during 7 months of therapy—thus,
However,

he was a non-responder.

he did not expire until 847 days after the start of therapy.

Second,

a 60-year-old woman with limited disease and performance

status 0 underwent a left lower lobectomy then received CAV therapy,
achieving complete response.

She was still alive at 907 days,

without

relapse.
Some toxicities were common but not severe enough to cause great
concern:

radiation esophagitis (never causing strictures or requiring

hospitalization);

nausea and vomiting (controllable); mucositis (never
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precluding oral food consumption); alopecia.

All were ECOG #2

(moderate toxicity) or better.
Myelosuppression significant enough to cause a drop in WBC count
to <2000 (ECOG #3 or worse) was experienced by 24 of 39 patients
(62%);

14 of 24 patients with ED (58%) and 10 of 15 with LD (67%);

treatment group:

by

16 of 21 CAV patients (76%); 8 of 18 CAV/E patients

(44%).
Anemia severe enough to require transfusion (ECOG #3) was
experienced by 9 of 39 patients overall (23%);
4 of 15 with LD (27%);
(17%).

6 of 21 on CAV (29%);

5 of 24 with ED (21%);

3 of 18 on CAV/E

Three patients require special mention;

one extensive disease

patient on CAV had a Hgb/Hct of 8.6/25.3 but no transfusion
documented; one LD-CAV/E patient had Hgb/Hct of 10.1/25.5 but refused
transfusion; one ED-CAV patient had chronic anemia status post Bilroth
II surgery and his anemia was not evaluable as a toxicity.
No platelet counts <50,000 (ECOG #3 or worse) were documented and
there were no episodes of bleeding.
Six patients were hospitalized 8 times for pneumonia;
of concurrent sepsis were documented.
three times for fever:

3 episodes

Two patients were hospitalized

one of these patients was hospitalized

separately for pneumonia, and is included among such patients above;
one patient was hospitalized twice with negative cultures but a left
upper lobe cavitary lesion on chest x-ray and a positive PPD test.
The latter patient was treated with INH and Rifampin.
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One patient was hospitalized once with a lung abcess and failure
to thrive.
One patient was hospitalized once for pancytopenia (WBC count of
300) but neither fever nor infection was documented.
Eight patients were thus considered to have been hospitalized at
some time for infection (all those described above except the patient
with pancytopenia only).

Seven of these 8 patients had ED; the one LD

patient was hospitalized twice,

once for pneumonia without sepsis,

once for fever only.
Thus,

7 of 24 ED patients (29%) experienced significant infection

as did 1 of 15 LD patients (7%);
18 CAV/E patients (6%).

7 of 21 CAV patients (33%); and 1 of

One patient not included above may have died

of treatment-related infection, as discussed below.
Two patients,
pneumonitis,

both with LD on CAV/E,

experienced radiation

one requiring treatment with steroids.

A third patient,

with ED on CAV, who had superior vena cava syndrome and liver
involvement at presentation,
chemotherapy cycle,
leukopenia,

fever,

was hospitalized 12 days after her last

5 weeks after radiation therapy to the chest,
chills,

Cultures were negative,

with

and bilateral pulmonary infiltrates.

but she was begun on antibiotics.

Her lung

disease was thought to be consistent with radiation pneumonitis,

but

this was diagnosed by chest x-ray and clinical impression only.

The

patient progressed to "Adult Respiratory Distress Syndrome" after one
week of hospitalization and expired two and one-half weeks after
admission.

This patient almost certainly died of treatment-related
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toxicity.

Infection is thought to be the most likely cause;

pneumonitis is a possibility.

radiation

The patient died without documented

relapse after a partial response to therapy.
One inevaluable patient had a possible treatment-related death.
She was a 70-year-old woman who presented with performance status 4,
SIADH and extensive disease.
50%.

Her cardiac ejection fraction was

She received one cycle of CAV therapy and had a sudden cardiac

death 48 hours later.
Three other patient deaths should be described.
A patient with LD on CAV therapy who received prophylactic
cranial irradiation (PCI) developed dementia,
vision.

Her CNS symptoms progressed, and,

dizziness,

and double

in light of a lumbar

puncture and CT scan negative for tumor,

she was felt to have died of

paraneoplastic encephalopathy.

combined Adriamycin-radiation

However,

therapy toxicity cannot be ruled out.
One patient with ED, a non-responder to CAV therapy,
dementia with memory loss and confusion.
progressed and,
tumor,

experienced

The patient’s CNS symptoms

in light of a CT scan and lumbar puncture negative for

his death was felt to be consistent with paraneoplastic

encephalopathy.

The patient received no PCI. However,

death due to

toxicity of chemotherapy alone cannot be ruled out.
Finally, a 58-year-old man presented with significant liver
involvement,
3.

bilateral lymphadenopathy, and performance status of

He was randomized to CAV/E therapy and died due to progression of

his disease in the liver 6 days after his only therapy cycle, which
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consisted of CAV.

This patient is mentioned because his case will be

noted in the discussion of treatment results later in the paper.
Three patients experienced significant cutaneous infections.
patients—one LD on CAV/E,

Two

one ED on CAV—experienced H. simplex

infections while being hospitalized for concurrent problems.

An ED

patient on CAV/E experienced an H. Zoster infection as an outpatient.
Three patients had rash reactions to chemotherapy:

one to

Adriamycin; one to Adriamycin and cyclophosphamide or cyclophosphamide
alone; one unknown.

Two patients required treatment with IV

steroids.
Adriamycin had to be discontinued in 2 patients due to
cardiotoxicity.
#2).

None experienced heart failure (both toxicities ECOG

One inevaluable patient experienced heart failure after a single

cycle of chemotherapy which did not contain Adriamycin.

Chemotherapy

was discontinued at the patient's request.
Vincristine neurotoxicity was significant enough to cause
discontinuation of the drug in 4 patients (3 LD on CAV;
CAV/E).

1 ED on

One of these patients (ED) experienced "Etoposide accentuated

vincristine neuropathy with foot drop" and both drugs were
discontinued.

The only other documented attenuation of Etoposide was

one cycle of 3 doses for myelosuppression just before the patient
relapsed.

Vincristine dose attenuation of more than 50% was required

in 4 patients (2 ED-CAV;

1 ED-CAV/E;

1 LD-CAV) for whom

discontinuation of the drug was not necessary.

67

Finally,

7 patients required significant attenuations (>50%) in

the dose of their chemotherapy (cyclophosphamide and/or Adriamycin)
for myelosuppression alone:

3 ED-CAV;

1 ED-CAV/E; 2 LD-CAV/E;

1

LD-CAV.

Discussion

The International Association for the Study of Lung Cancer
Workshop has published its treatment result expectations for
SCCL.^

Expectations include complete response of 50% in LD and 20%

in ED; median survival of at least 14 months in LD and 7 months in ED;
and 15-20% 3 year disease-free survival among LD patients.

These

expectations may be excessively optimistic (especially those for
long-term survival—see Table 8),
standard for comparison.
selected studies;

but at least they establish some

Table 7 presents treatment results from

direct comparisons are not possible between

studies.
The response rates in the present series were generally good,
with 80% of LD patients achieving complete response.

Just 12% of ED

patients achieved complete response, a low but acceptable number.
Projected median survival was very good,

ranging from about 6.5

months for ED non-responders to more than 18 months for LD complete
responders.

As expected,

both time to relapse and survival were

significantly longer for LD responders (CR + PR) than for ED
responders.

The presence in the ED non-responder group of a patient

who survived 847 days after a choroidal relapse must be kept in mind
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when evaluating the projected survival data for this relatively small
group (n=9).

The unusual choroidal relapse appears to have had no

significant negative influence on this patient's survival.

The

projected median survival of 560 days for LD complete responders must
also be approached with some caution since the projection is based on
data from 12 patients,

8 of whom were still living.

The living

patients had a median follow-up of just 305 days.
Of the 12 LD patients achieving complete response,

one was alive

and disease-free at 907 days (slightly less than 2.5 years).
Interestingly,
protocol,

this patient had surgery prior to beginning the

adding further anecdotal evidence to the efficacy of

adjuvant surgery in achieving local control and the importance of
local control in long-term survival.

In fact,

it is too soon to

predict the number of long-term survivors from this study.
The two treatment groups were very similar in survival results.
The CAV/E group had shorter projected median survival in both ED and
LD,

but no comparison with CAV survival curves was significant.

Time

to relapse was shorter for the ED-CAV/E group than the ED-CAV group
and the comparison was barely significant (j)=.Q4).

Further

subgrouping showed a significantly shorter time to relapse for the ED
non-responders on CAV/E than those on CAV.

Comparison of time to

relapse for ED responders was not significantly different for the two
treatment groups.

There are numerous reasons for quicker time to

relapse in ED non-responders on CAV/E.

These include the fact that

the ED-CAV/E group contained a substantially smaller proportion of
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fully ambulatory patients than the ED-CAV group (62% vs.

27%).

The ED

non-responder CAV group contained that patient with the choroidal
relapse who went on to relatively long survival while the ED-CAV/E
non-responder group contained the patient who died of progressive
disease in only 6 days.

ED non-responders on CAV survived longer than

ED non-responders on CAV/E but the groups are small and comparison
didn't quite reach significance (_p_=.053).

Interestingly,

better for the ED responders on CAV/E than those on CAV,

survival was
but the

comparison was not significant (j>=.41).
Clearly,

the addition of Etoposide to CAV produced no difference

m treatment results worthy of mention.

lwo previous reports

139,140

cited better response rates with the addition of Etoposide to CAV;
still,

the studies found no significant differences between the

treatment groups in survival.
No unexpected toxicities arose in the study.

Myelosuppression

was no greater than that consonant with a good therapeutic response.
Etoposide added no apparent additional toxicity to the CAV
regimen.

In fact,

only 1 of the 18 CAV/E patients (6%) required

hospitalization for infection versus 7 of the 21 CAV patients
(33%).

The 33% rate for CAV patients is higher than the 11.7%

"standard" infection rate for combined modality protocols cited in one
review of SCCL treatment complications.
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The 6% rate with CAV/E is

lower than the "standard" rate and unexpected.

Leukopenia (WBC count

<2000) was experienced by 16 of 21 CAV patients (76%) versus 8 of 18
CAV/E patients (44%).

Perhaps this underlies the difference in
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infection rates,

unless Etoposide has some heretofore undiscovered

antibiotic properties.
One treatment-related death was probably caused by infection
(although radiation pneumonitis is possible),
infection rate of 1 in 39 patients (2.6%).
combined modality study.
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yielding a fatal

This is reasonable for a

Sudden cardiac death occurred after a

single cycle of cyclophosphamide and vincristine in a patient
presenting with extensive disease, SIADH,

poor performance status

(bedridden) and a cardiac ejection fraction of 50%.

This must be

viewed as a possible treatment-related death although no Adriamycin
was given.
In summary,

the present study employed state-of-the-art design

(prophylactic cranial irradiation after complete response,

thoracic

irradiation in limited disease, and use of Etoposide, an agent with
significant activity against SCCL) and achieved early treatment
results comparable to those in the current literature.

It is too

early to evaluate long-term survival.
Addition of Etoposide to CAV therapy yielded no improvement in
initial treatment results,

including survival.

However, an

unexpectedly low rate of infections requiring hospitalization was
found in the CAV/E group,
group,

141

substantially lower than that in the CAV

perhaps secondary to a lower rate of leukopenia with the use

of Etoposide in half the treatment cycles.
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a day

1-2 packs
a day

14.5%

19.2%

23.9%

2+ packs
a day

31.1%

Total subjects = 163

From:
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Table J_ — Age Standardized Percentage Distribution of SCCL by
Cigarette Smoking Habit

Exposure Group+

Excess Cases

1 - 359

8.27*

360 - 1779

22.07*

> 1800

33.69*

Combined groups

64.03*

* = significantly different from expected number of cases (£.<.01)

+Exposure is quantified by "Working Level Month" (WLM) Groups.
One
WLM is a month's work performed in an atmosphere containing a standard
radiation dose per liter of air.

From:

Archer, J.E., Saccomano, G., and Jones, J.H.
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Table 2. — Distribution of Excess (Presumably Radiation-Induced)
Bronchogenic Cancers by Radiation Exposure Group
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Percentage of patients with the symptom

Symptom

Cohen and Matthews

[12]

Friesenhahn,

Cough

76

37

Chest pain

36

28

Dyspnea

34

31

Pneumonitis

25

NR

Wheeze

22

NR

Hemoptysis

15

17

Fatigue

NR

21

Hoarseness

15

NR

SVC syndrome

12

NR

NR = Not Reported

Table 3. — Symptoms of SCCL

et al.

[44]
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At Presentation^"^
(total pts = 375)

At Autopsy^^
(total pts = 163)

Liver

32

61.7

Bone

30

35

Bone marrow

16

NR

Brain

14

50

Skin, soft tissue,
nodes

16

75.5 (excluding
"chest wall")

Effusion/pleura

15

22.7

Heart

NR

20.3

NR = Not Reported

From:

Livingston, R.B., Trauth, C.J., Greenstr^et, R.L.
Auerbach, 0., Garfinkel, L., Parks, V.
J

r 45 l
J and

Table 4. — Percent Distribution of Metastases at Presentation and
at Autopsy in Two Studies
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Procedure

Sue

Recommended

Primary

Chest X-ray
Fiberoptic bronchoscopy

4

Mediastinum

Mediastinoscopy*
Gallium scan

4

Bone marrow

Biopsy and aspiration
Bilateral biopsies
Scintigrams

4

Liver

Peritoneoscopy and
liver biopsy
Ultrasonography
CT scan

If positive
initially

Lymph nodes and skin Fine-needle aspiration
CNS

CT scans
Scintigrams
Lumbar puncture
Myelograms

Retroperitoneal
organs

CT scans
Ultrasonography
Laparotomy

4

•Whenever possible

From

Osterlind K.,

Ihde, D.C.

If signs'
symptoms

et al

[57]

Table _5 — Recommendations for Restaging

Definite

Stage of disease
Performance status

Probable

Liver or CNS metastases
Laboratory parameters

Possible

Weight loss
Number of metastatic sites
Age
Sex
Size of lesion ("very limited" vs. other)

None

Histologic subtype (1977 WHO classification)

Investigational

Histologic subtype (small cell-large cell vs
classic small cell)+

Adapted from Ihde D.C., and Hansen, H.H.[48]

+Proposed by pathology panel of the International Association for the
Study of Lung Cancer.[73b]

Table 6_ — Prognostic Factors in SCCL
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Number
of Pts

Complete
Response

Median Survival
(weeks)

Treatment

LD

ED

LD

ED

LD

Placebo^4^ ^

38

108

+

+

11.7

Placebo^88^

29

+

+

+

Surgery[90]

68

+

+

+

28.5a

+

Radiation^" ^

70

+

+

44a

+

p
a ■
[88]
Radiation

53

+

+

CAV + RT^94^

108

CME + RT^95J

(38 LD + ED)

250

>16

ED

5.0

+

>16

+

41%

14%

52

26

86%

27%

56

20

CAVE + RTt96^

33

11

76%

34%

92

36

CAVE + RT^- 97 ^

28

29

61%

21%

60

37

MEV/ CAV / ^98 ^
MEV - CAV

+

453

+

16%

+ = Inapplicable
'x' = Not Reported
a = Mean Survival

C = cyclophos phamide
A = Adriamycin
V = vincristine

Table 7 — Treatment Results in SCCL:

+

31

M = methotrexate
RT = Radiation Therapy
E = Etoposide
(VP 16-213)

Selected Studies

92

Number of
Patients

Treatment

Patient
Characteristics

Long-Term
Survivors

c
[90]
Surgery

58

All LD

0% LD

Radiation ^ ^ ^

70

All LD

5% LD

Chemotherapy

RT^ 8Z* ^

CAV + RT^86^

+ = Not Reported
C = cyclophosphamide

255

+

400

100 LD
300 ED

RT = Radiation Therapy
A = Adriamycin (doxorubicin)
V = vincristine

Table 8 — Long-Term Survival (_>5 years) in SCCL

6% LD + ED

4% (LD + ED)
11% LD
2% ED

GROUP 1- United Disease

Treatment Schema

iff «cu >

L KQC
^■OHU

I

< U>
«c
la b I e 9^ — Treatment Protocol

«<u>

^ «c

»<u>
for Limited Disease

e<u>

Txoc

< U>

Ur

Treatment Schema
GROUP 2 *

Extensive Disease

cycle
1
Adri a
CTX

Diagnosis

>/TVCR

-

3
A
C
V

2
A
C
V

Elective
Rad Rx

5
A
C
V

1

Adria : Adriamycin 40 mg/m

VCR

7
A
C
V

8
A
C
V

9
A
C
V
R
E

5
T
A

Adri a
A
A
A
A
CTX
VP-16 C VP-16 C VP-16 C VP-16 C VP-16
VCR
V
V
V
V

X3

cycle

CTX

6
A
C
V

Prophylactic
Whole Brain Rad

j

CTX
VCR

4
A
C
V

M

S

6

X

E

2

1

IV day 1
2
: Cyclophosphamide 1000 mg/m IV day 1
2
: Vincristine 1.4 mg/m IV day 1 (each dose limited to 2 mg total)
VP-16 125 mg/m^ IV days 1, 3, 5

Table 10 — Treatment Protocol for Extensive Disease

CAV Therapy Patients
10 females:

11 males

Median age (range):
Subgroup:

n = 21 (54%)

59 years (49-71)

CAV - Limited Disease Patients

n = 8 (38%)

P.S. 0 = 1-P.S. 1 = 5 -—-

6 pts. fully am
(75%)

P.S. 2 = 0~___
P.S. 3 = 1
P.S. 4 = 0-—

1 pt. not fully
ambulatory
(12%)

P.S. unknown = 1
Subgroup:

CAV - Extensive Disease Patients
P.S. 0 = 0P.S. 1 = 8-"

pts. fully ambulatory
(62%)

P.S. 2 = 4-____
P.S. 3=0
P.S. 4 = 1—

5 pts. not fully
ambulatory
(38%)

CAV/E Therapy Patients
10 females:

Subgroup:

n = 18 (46%)

8 males

Median age (range):
Subgroup:

n = 13 (62%)

66 years (53-72)

CAV/E - Limited Disease Patients
P.S. 0=3
P.S. 1 = 2

5 pts.
(71%)

P.S. 2=2
P.S. 3=0
P.S. 4=0

2 pts. not fully
ambulatory
(29%)

n = 7 (39%)

fully ambulatory

CAV/E - Extensive Disease Patients

n = 11 (61%)

P.S. 0 = i—--—_____ 3 pts. fully ambulatory
(27%)
P.S. 1 = 2 ——- ''—
P.S. 2 = 4 —_____
P.S. 3=3
P.S. 4 = 1——'
E = Etoposide (VP-16-213)
A = Adriamycin (doxorubicin)

8 pts. not fully
ambulatory
(73%)
C = cyclophosphamide
V = vincristine

Table 11 — Patient Characteristics by Treatment Arm
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Number of pts
with disease
at site+
Site

% of ED pts
with disease
at site

Number of pts with
this site as only
involvement beyond
primary tumor

CAV

CAV/E

CAV

CAV/E

Liver

8

6

62%

55%

3

Bone

7

5

54%

45%

1

Bone Marrow

6

1

46%

9%

2

Nodes (excluding chest)

3

2

23%

18%

-

Pleura

2*

2**

15%

18%

-

Bilateral Lung

1

1

8%

9%

-

Subcutaneous Nodules

2

-

.5%

-

-

Brain

-

1

-

9%

-

Neither confirmed1 by cytology
'x"* 1 of 2 confirmed by cytology

+ Total ED patients = 24
ED-CAV = 13
ED-CAV/E = 11

Table 12 — Metastatic Sites at Diagnosis in Extensive Disease (ED)
Patients by Treatment Arm

97

Number of patients
with relapse at site+

Site

% of all patients who
who relapsed ,

Chest (excluding pleura)

9

23%

Liver

7

18%

Bone

5

13%

Brain

5

13%

Nodes (excluding chest)

4

10%

Pleura

2*

5%

Bone Marrow

1

3%

Subcutaneous Nodules

1

3%

Others CNS (choroidal)

1

3%

Neither confirmed by cytology; one recurrent

Relapses at Sites of Initial Disease*
Site

Number of Relapses

Liver

4

Bone

3

Nodes (excluding chest)

2

Pleura

1

* Excludes chest relapses, except in pleura

Table 13 — Sites of Relapse

+Total pts = 39

98

Response to Therapy by Stage and Treatment Arm
CR

PR

NR

All patients (n=39) (no.(%))

15 (38%)

13 (33%)

11 (28%)

Limited Disease (n=15)

12 (80%)

1 ( 7%)

2 (13%)

Extensive Disease (n=24)

3 (12%)

12 (50%)

9 (38%)

CAV-LD (n=8)

7 (88%)

1 (12%)

0

CAV/E-LD (n=7)

5 (71%)

0

2 (29%)

CAV-ED (n=13)

2 (15%)

7 (54%)

4 (31%)

CAV/E-ED (n=l1)

1 ( 9%)

5 (45%)

5 (45%)

Time to Relapse
Group

Median (pro jected)

LD- CR+PR

361 days

ED- CR+PR

188 days

ED- NR

71 days

CAV-LD

334 days

CAV/E-LD

361 days

CAV-ED

193 days

CAV/E-ED

109 days

p-value

.55

.04

LD
CR
NR
C
V

=
=
=
=
=

Limited-stage disease
Complete response
Non-responders
cyclophosphamide
vincristine

Table 14 — Treatment Results:

ED = Extensive-stage disease
PR = Partial response
A
E

= Adriamycin (doxorubicin)
= Etoposide (VP-16-213)

Response and Time to Relapse

99

Group

Median (pro jected)

All patients

301 days

LD - CR

560 days

LD- CR+PR

560 days

ED- CR+PR

230 days

ED- NR

198 days

CAV-LD

560

CAV/E-LD

424

CAV-ED

230

CAV/E-ED

186

p-value

2.

=

R

=

.0007
.24

.24

.23

LD
CR
NR
C
V

=
=
=
=
=

Limited-stage disease
Complete response
Non-responders
cyclophosphamide
vincristine

Table 15 — Survival

ED = Extensive-stage disease
PR = Partial response
A
E

= Adriamycin (doxorubicin)
= Etoposide (VP-16-213)
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Figure 2 — Time to Relapse for Extensive Disease Patients by Response Group
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Figure 8 — Survival
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Figure 9 — Survival

> >
<c <c
o o
II II
<c CQ

for Extensive Disease Patients by Treatment Group

w

.

,.1E ;

DICAL LIBRARY

J?!onuscript Theses

hC CO

Unpublished thes »r submitted for the Master *o and Doctor’s
deposited in the YeLe Men i-nil Library are to be used only with due
hts of the authors.
Bibliographical references in ay be noted, bu
t not be copied -without permission of the authors , and without p
being given in subseraent written or published work.

This thesis by
used by the following persons, whose signatures atte st their accept
hove restrictions.

NAME AND ADDRESS

